Revolutions Medical (RMCP) Inactive 10-K14 Apr 142013 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2013	Apr. 14, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Revolutions Medical CORP	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	112,767,433	'
Entity Public Float	'	'	$5,659,820
Amendment Flag	'false	'	'
Entity Central Index Key	'0001041009	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash and cash equivalents	$932	$54
Inventory	278,564	321,791
Prepaid expenses and other current assets	2,932	4,859
Total current assets	282,428	326,704
Property and equipment, net	270,189	356,656
Intangibles, net	133,517	106,687
Total assets	686,134	790,047
Accounts payable and accrued liabilities	1,867,192	1,122,371
Accounts payable and accrued liabilities, related parties	132,407	73,957
Unearned revenue	73,495	'
Payable for indemnification	1,376,084	1,347,806
Convertible notes, net of discounts of $247,661 and $187,039, respectively	494,708	184,289
Convertible notes, related parties, net of discounts of $0 and $42,534, respectively	75,000	32,466
Derivative liability, note conversion feature	658,453	364,802
Total liabilities	7,924,434	4,406,551
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Series 2006 Preferred stock, $0.001 par value, 5,000,000 shares authorized; 1,000,000 shares issued and outstanding	1,000	1,000
Common stock, $0.001 par value; 250,000,000 shares authorized; 107,039,034 and 72,784,907 shares issued and outstanding, respectively	107,039	72,785
Additional paid-in-capital	37,087,921	34,319,432
Subscriptions receivable	-71,000	-71,000
Deficit accumulated during the development stage	-44,363,260	-37,938,721
Total stockholders' deficit	-7,238,300	-3,616,504
Total liabilities and stockholders' deficit	686,134	790,047
Yeso Med [Member]	'	'
Current Assets:	'	'
Payable to Yeso-med	$3,247,095	$1,280,860

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Convertible promissory notes, discount (in Dollars)	$247,661	$187,039
Convertible notes, related parties, discount (in Dollars)	$0	$42,534
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	107,039,034	72,784,907
Common stock, shares outstanding	107,039,034	72,784,907

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended		208 Months Ended
Statements of Operations (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	$41,419	$1,189	$42,608
Cost of revenue	19,833	9,200	29,033
Loss on firm purchase commitment	1,965,482	783,593	2,749,075
Cost of goods sold	1,985,315	792,793	2,778,108
Gross loss	-1,943,896	-791,604	-2,735,500
Operating expenses:	'	'	'
Research and development	0	35,544	2,935,949
Depreciation and amortization	98,005	102,971	303,116
General and administrative expenses	3,800,405	4,046,080	31,099,209
Impairment of assets	'	878,276	4,570,007
Gain on disposal of assets	'	'	-794
Total operating expenses	3,898,410	5,062,871	38,907,487
Operating loss	-5,842,306	-5,854,475	-41,642,987
Other income (expense):	'	'	'
Interest income	'	'	17,286
Interest expense	-852,271	-1,727,512	-3,481,976
Investment income	'	'	170,753
Gain (loss) on extinguishment of debt	-34,202	13,202	-173,914
Gain on change in fair value of derivative liabilities	304,994	131,397	259,018
Other income (expenses), net	-754	273,077	305,138
Total other income (expense)	-582,233	-1,309,836	-2,903,695
Net loss	-6,424,539	-7,164,311	-44,546,682
Net loss attributable to the non-controlling interest	'	'	-183,422
Net loss attributable to Revolutions Medical Corp.	($6,424,539)	($7,164,311)	($44,363,260)
Net loss per common share - basic and diluted (in Dollars per share)	($0.07)	($0.12)	'
Weighted average number of common shares outstanding - basic and diluted (in Shares)	91,264,327	61,779,765	'

Statements_of_Stockholders_Equ

Statements of Stockholders’ Equity (USD $)

Common Stock Issued Pursuant to Joint Venture [Member]

Warrants Granted Pursuant to Joint Venture [Member]

Exercises by Third-parties for Services [Member]

Exercises by Third Parties for Cash [Member]

Common Stock Issued for Services [Member]

Exercise of Warrants for Cash [Member]

Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit during Development Stage [Member]

Receivables from Stockholder [Member]

Treasury Stock [Member]

Employee Stock Option [Member]

Common Stock Issued for Services [Member]

Preferred Stock Issued for Services [Member]

Equity Option [Member]

Third-Party Investors [Member]

Services Rendered by Third Parties [Member]

Exercises by Third Parties for Cash [Member]

Exercises by Third-parties for Services [Member]

Services Contributed by Officer and Employees [Member]

Options Granted to Non-employees [Member]

Stock Issued for Services [Member]

Warrant [Member]

Cerro Mining [Member]

Maxxon-OK, Founders [Member]

Maxxon-OK, Third-Party [Member]

Ives, Health Company [Member]

Ives, Health Club [Member]

Ives, Debt [Member]

Clear Image Acquisition Corp [Member]

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Receivables from Stockholder [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Preferred Stock Issued for Services [Member]

Common Stock Issued for Services [Member]

Third-Party Investors [Member]

Services Rendered by Third Parties [Member]

Exercises by Third Parties for Cash [Member]

Exercises by Third-parties for Services [Member]

Stock Issued for Services [Member]

Warrant [Member]

Cerro Mining [Member]

Maxxon-OK, Founders [Member]

Maxxon-OK, Third-Party [Member]

Ives, Health Company [Member]

Ives, Health Club [Member]

Ives, Debt [Member]

Clear Image Acquisition Corp [Member]

Common Stock Issued for Services [Member]

Preferred Stock Issued for Services [Member]

Equity Option [Member]

Third-Party Investors [Member]

Services Rendered by Third Parties [Member]

Exercises by Third Parties for Cash [Member]

Exercises by Third-parties for Services [Member]

Services Contributed by Officer and Employees [Member]

Options Granted to Non-employees [Member]

Stock Issued for Services [Member]

Warrant [Member]

Cerro Mining [Member]

Maxxon-OK, Founders [Member]

Maxxon-OK, Third-Party [Member]

Ives, Health Company [Member]

Ives, Health Club [Member]

Ives, Debt [Member]

Clear Image Acquisition Corp [Member]

Balance at Aug. 15, 1996

Business Acquisition

$27

$350

$29

$16

$273

$6,650

$574,448

$311,246

$34,998

$300

$7,000

$574,477

$311,262

$35,000

Business Acquisition, Shares (in Shares)

26,550

350,000

28,900

15,562

1,750

Convertible Debt

26,999

128,997

27,000

129,000

Convertible Debt, Shares (in Shares)

926

3,225

Subscriptions

69,798

-69,800

Subscriptions, Shares (in Shares)

2,638

Issued for Services

173,423

173,427

Issued for Services, Shares (in Shares)

4,525

Debentures

74,995

75,000

Debentures, Shares (in Shares)

5,134

Net Income

-795,376

Issued for Cash

353,709

353,720

Issued for Cash, shares (in Shares)

10,928

Balance at Dec. 31, 1997

450

1,755,536

-795,376

-69,800

890,810

Balance, Shares (in Shares) at Dec. 31, 1997

450,138

Convertible Debt

54,998

55,000

Convertible Debt, Shares (in Shares)

2,241

Subscriptions

69,800

Issued for Services

574,499

114,154

574,548

114,154

Issued for Services, Shares (in Shares)

49,400

Compensation Cost

918,187

Debentures

274,973

275,000

Debentures, Shares (in Shares)

27,429

Net Income

-2,584,383

Issued for Cash

90,997

332

91,000

350

Issued for Cash, shares (in Shares)

2,500

17,500

Certificates canceled

-4

-40,261

-40,265

Certificates canceled (in Shares)

-4,579

Exercises of Options

359,873

18,099

359,900

18,100

Exercises of Options, Shares (in Shares)

27,293

1,207

Balance at Dec. 31, 1998

573

4,121,387

-3,379,759

742,201

Balance, Shares (in Shares) at Dec. 31, 1998

573,129

Issued for Services

166,735

280,000

166,743

280,000

Issued for Services, Shares (in Shares)

8,203

Compensation Cost

89,728

Net Income

-1,014,555

Issued for Cash

342,404

342,424

Issued for Cash, shares (in Shares)

19,535

Issuance Cost

-16,743

Exercises of Options

149,985

150,000

Exercises of Options, Shares (in Shares)

15,000

Balance at Dec. 31, 1999

616

5,133,496

-4,394,314

739,798

Balance, Shares (in Shares) at Dec. 31, 1999

615,867

Issued for Services

405,000

Net Income

-1,347,859

Issued for Cash

250,345

250,388

Issued for Cash, shares (in Shares)

43,139

Balance at Dec. 31, 2000

659

5,788,841

-5,742,173

47,327

Balance, Shares (in Shares) at Dec. 31, 2000

659,006

Convertible Debt

7,497

7,500

Convertible Debt, Shares (in Shares)

2,500

Issued for Services

422,427

1,487,690

422,450

1,487,700

Issued for Services, Shares (in Shares)

22,500

10,000

Amortization of Compensation Cost

-1,048,754

Net Income

-2,199,085

Issued for Cash

328

183

1,604,372

547,317

-547,500

1,604,700

Issued for Cash, shares (in Shares)

327,917

182,500

Issuance Cost

-85,575

Balance at Dec. 31, 2001

1,206

8,723,815

-7,941,258

-547,500

236,263

Balance, Shares (in Shares) at Dec. 31, 2001

1,204,423

Convertible Debt

102,803

Compensation Cost

324,440

324,500

Compensation Cost, Shares (in Shares)

60,000

Net Income

-1,933,676

Issued for Cash

181

362,319

362,500

Issued for Cash, shares (in Shares)

181,250

Issuance Cost

759,795

Exercises of Options

100

-100

Exercises of Options, Shares (in Shares)

100,341

Balance at Dec. 31, 2002

1,547

10,170,269

-9,874,934

-444,697

-147,815

Balance, Shares (in Shares) at Dec. 31, 2002

1,546,014

Convertible Debt

69,201

Amortization of Compensation Cost

288,959

Compensation Cost

350

139,650

140,000

Compensation Cost, Shares (in Shares)

350,000

Net Income

-1,391,518

Issuance Cost

200

79,800

80,000

Issuance Cost, Shares (in Shares)

200,000

Exercises of Options

140,643

140,700

Exercises of Options, Shares (in Shares)

57,000

Balance at Dec. 31, 2003

2,154

10,819,321

-11,266,452

-375,496

-820,473

Balance, Shares (in Shares) at Dec. 31, 2003

2,153,014

Convertible Debt

18,750

Issued for Services

1,643

912,357

914,000

Issued for Services, Shares (in Shares)

1,642,500

Net Income

-1,552,008

Issued for Cash

4,995

5,000

Issued for Cash, shares (in Shares)

5,000

Exercises of Options

293

253,807

254,100

Exercises of Options, Shares (in Shares)

293,300

Exercise of Warrants

73,027

-1,000

72,100

Exercise of Warrants, Shares (in Shares)

73,100

Balance at Dec. 31, 2004

4,168

12,063,507

-12,818,460

-357,746

-1,108,531

Balance, Shares (in Shares) at Dec. 31, 2004

4,166,914

Business Acquisition

292

137,541

137,833

499,733

Business Acquisition, Shares (in Shares)

291,667

Subscriptions

260

33,740

-34,000

Subscriptions, Shares (in Shares)

260,000

Issued for Services

1,063

475,437

476,500

Issued for Services, Shares (in Shares)

1,062,500

Compensation Cost

130,900

Reclassification of receivables against amounts owed

357,746

Net Income

-1,310,783

Issued for Cash

652

290,048

290,700

Issued for Cash, shares (in Shares)

651,959

Exercises of Options

44,910

45,000

Exercises of Options, Shares (in Shares)

90,000

Balance at Dec. 31, 2005

6,525

13,675,816

-14,129,243

-34,000

-480,902

Balance, Shares (in Shares) at Dec. 31, 2005

6,523,040

Subscriptions

34,000

Issued for Services

1,000

275

107,225

19,000

107,500

20,000

Issued for Services, Shares (in Shares)

1,000,000

275,000

Capital contributed by shareholder

3,000

Compensation Cost

50,000

Debentures

-625,066

Treasury Stock

-25

-12,475

-12,500

Treasury Stock, shares (in Shares)

-25,000

Net Income

-598,302

Exercises of Options

950

1,000

150

74,850

75,000

Exercises of Options, Shares (in Shares)

50,000

150,000

Exercise of Warrants

300

5,700

6,000

Exercise of Warrants, Shares (in Shares)

300,000

Balance at Dec. 31, 2006

1,000

7,275

13,299,000

-14,727,545

-1,420,270

Balance, Shares (in Shares) at Dec. 31, 2006

1,000,000

7,273,040

Business Acquisition

8,274

3,301,241

3,309,515

Business Acquisition, Shares (in Shares)

8,273,788

Issued for Services

1,225

388,775

390,000

Issued for Services, Shares (in Shares)

1,225,000

Issuance of restricted stock

9,960

10,000

Issuance of restricted stock (in Shares)

40,000

Compensation Cost

223,246

Net Income

-4,475,017

Issued for Cash

845

299,155

300,000

Issued for Cash, shares (in Shares)

845,000

Exercises of Options

125

9,875

10,000

Exercises of Options, Shares (in Shares)

125,000

Exercise of Warrants

346

6,568

6,914

Exercise of Warrants, Shares (in Shares)

345,662

Balance at Dec. 31, 2007

1,000

18,130

17,537,820

-19,202,562

-1,645,612

Balance, Shares (in Shares) at Dec. 31, 2007

1,000,000

18,127,490

Business Acquisition

12,164

12,207

Business Acquisition, Shares (in Shares)

43,600

Convertible Debt

271

132,759

133,030

Convertible Debt, Shares (in Shares)

271,491

Issued for Services

1,419

258,501

259,920

Issued for Services, Shares (in Shares)

1,419,704

Compensation Cost

342,801

Acquired deficit of former Minority interest now Owned 100%

-209,776

Net Income

-1,335,154

Issued for Cash

4,722

300,101

304,823

Issued for Cash, shares (in Shares)

4,720,978

Exercises of Options

2,300

395,317

397,617

Exercises of Options, Shares (in Shares)

2,300,000

Balance at Dec. 31, 2008

1,000

26,885

18,769,687

-20,537,716

-1,740,144

Balance, Shares (in Shares) at Dec. 31, 2008

1,000,000

26,883,193

Convertible Debt

667

306,074

306,741

Convertible Debt, Shares (in Shares)

667,000

Issued for Services

500

249,500

250,000

Issued for Services, Shares (in Shares)

500,000

Compensation Cost

1,452,231

Acquired deficit of former Minority interest now Owned 100%

-17,998

Net Income

-2,463,751

Issued for Cash

5,946

1,396,188

1,402,134

Issued for Cash, shares (in Shares)

5,946,446

Exercises of Options

171

13,529

13,700

1,530

346,770

348,300

Exercises of Options, Shares (in Shares)

171,250

1,530,000

Balance at Dec. 31, 2009

1,500

35,199

22,515,981

-23,001,467

-448,787

Balance, Shares (in Shares) at Dec. 31, 2009

1,500,000

35,197,959

Convertible Debt

400

530,356

530,756

Convertible Debt, Shares (in Shares)

399,441

Issued for Services

2,194

558,578

560,772

Issued for Services, Shares (in Shares)

2,194,891

Treasury Stock

-969

Net Income

-3,231,425

Issued for Cash

4,810

1,525,181

1,529,991

Issued for Cash, shares (in Shares)

4,810,287

Exercises of Options

150

37,350

37,500

Exercises of Options, Shares (in Shares)

150,000

Exercise of Warrants

117

58,583

58,700

Exercise of Warrants, Shares (in Shares)

117,400

Balance at Dec. 31, 2010

1,500

42,870

25,226,029

-26,232,892

-969

-963,462

Balance, Shares (in Shares) at Dec. 31, 2010

1,500,000

42,869,978

Business Acquisition

656

201,915

202,571

Business Acquisition, Shares (in Shares)

656,015

Convertible Debt

3,191

959,105

962,296

Convertible Debt, Shares (in Shares)

3,191,367

From convertible debt beneficial conversion feature

94,624

Issued for Services

1,514

479,586

481,100

Issued for Services, Shares (in Shares)

1,513,874

Treasury Stock

-169

969

800

Treasury Stock, shares (in Shares)

-169,628

Issuance of unexercised options

863,426

Net Income

-4,541,518

Exercises of Options

6,668

1,672,752

-25,000

1,654,420

Exercises of Options, Shares (in Shares)

6,668,000

Preferred stock forfeited

-500

500

Preferred stock forfeited (in Shares)

-500,000

Balance at Dec. 31, 2011

1,000

54,730

29,497,937

-30,774,410

-25,000

-1,245,743

Balance, Shares (in Shares) at Dec. 31, 2011

1,000,000

54,729,606

Exercise of Options and Warants for Cash

1,235

303,040

-46,000

258,275

Exercise of Options and Warants for Cash (in shares) (in Shares)

1,235,000

Convertible Debt

13,669

2,305,103

2,318,772

Convertible Debt, Shares (in Shares)

13,669,072

Common stock issued for indemnification settlement

400

140,160

140,560

Common stock issued for indemnification settlement (in Shares)

400,000

From convertible debt beneficial conversion feature

237,774

Issued for Services

2,751

513,360

974,961

516,111

974,961

Issued for Services, Shares (in Shares)

2,751,229

Warrants Issued with Convertible Notes Payable

347,097

Compensation Cost

1,491,072

Net Income

-7,164,311

Exercises of Options, Shares (in Shares)

575,000

Balance at Dec. 31, 2012

1,000

72,785

34,319,432

-37,938,721

-71,000

-3,616,504

Balance, Shares (in Shares) at Dec. 31, 2012

1,000,000

72,784,907

Exercise of Options and Warants for Cash

2,600

136,900

139,500

Exercise of Options and Warants for Cash (in shares) (in Shares)

2,600,000

Convertible Debt

13,753

353,246

366,999

Convertible Debt, Shares (in Shares)

13,753,045

Common stock pledged as collateral

9,375

-9,375

9,375

Common stock pledged as collateral (in Shares)

9,375,000

Common stock cancelled

-267

267

-267

Common stock cancelled (in Shares)

-266,666

From convertible debt beneficial conversion feature

170,639

Common stock issued to settle accounts payable and accrued liabilities

4,417

246,057

250,474

Common stock issued to settle accounts payable and accrued liabilities (in Shares)

4,416,617

Issued for Services

4,376

355,127

1,227,752

359,503

609,977

Issued for Services, Shares (in Shares)

4,376,131

Warrants issued for services

74,915

Warrants Issued with Convertible Notes Payable

2,588

Warrant modification

210,373

Compensation Cost

1,662,170

Net Income

-6,424,539

Exercises of Options, Shares (in Shares)

2,500,000

Balance at Dec. 31, 2013

$1,000

$107,039

$37,087,921

($44,363,260)

($71,000)

($7,238,300)

Balance, Shares (in Shares) at Dec. 31, 2013

1,000,000

107,039,034

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended		208 Months Ended
Statements of Cash Flows (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities:	'	'	'
Net loss	($6,424,539)	($7,164,311)	($44,363,260)
Depreciation and amortization	98,005	102,971	303,116
Stock-based compensation	1,662,170	1,491,072	14,278,901
Stock options and warrants modification expense	210,373	'	260,373
Impairment of assets	'	878,276	4,570,007
Gain on disposal of assets	'	'	-794
Amortization of debt discounts	571,639	1,428,978	2,432,857
Interest expense incurred on issuance of convertible debt	200,404	182,733	596,878
Loss (gain) on extinguishment of debt	34,202	-13,202	173,914
Gain on change in fair value of derivative liabilities	-304,994	-131,397	-259,018
Changes in operating assets and liabilities:	'	'	'
Inventory	43,227	-321,791	-278,564
Prepaid expenses and other current assets	1,927	275,009	-2,932
Accounts payable and accrued liabilities	2,987,163	1,546,960	5,700,094
Accounts payable and accrued liabilities - related parties	45,950	-13,987	119,907
Unearned revenue	73,495	'	73,495
Payable for indemnification	28,278	64,347	1,833,674
Net cash used in operating activities	-772,700	-1,674,342	-14,561,352
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	'	'	-992,907
Proceeds from sale of fixed assets	'	'	794
Payments for license and patents	-38,368	-39,224	-199,906
Investment in Ives Health Company and The Health Club	'	'	-261,997
Net cash used in investing activities	-38,368	-39,224	-1,454,016
Cash flows from financing activities:	'	'	'
Capital contribution	'	'	802,154
Proceeds from issuance of common stock through cash exercise of stock options and warrants	127,000	258,275	3,539,412
Proceeds from issuance of notes for cash	762,602	1,450,501	3,738,603
Proceeds from loans from shareholders	'	'	15,707
Repayment of loans from shareholders	'	'	-8,005
Repayment of notes	-77,656	'	-234,981
Proceeds for issuance of common stock for cash	'	12,500	8,163,410
Net cash provided by financing activities	811,946	1,708,776	16,016,300
Net change in cash	878	-4,790	932
Cash at beginning of period	54	4,844	'
Cash at end of period	932	54	932
Supplemental disclosure of cash flow information:	'	'	'
Interest paid	11,480	0	11,480
Taxes paid	0	0	0
Non-cash investing and financing activities:	'	'	'
Common stock issued for conversion of debt	617,473	2,318,772	5,304,888
Shares issued for indemnification agreement	'	140,560	457,590
Debt discount on convertible notes	568,879	584,871	2,974,301
Common stock issued for investment	'	'	358,762
Preferred stock forfeited	'	'	500
Payable recorded for purchase of equipment	'	'	289,009
Cancellation of shares	267	'	267
Shares pledged for TCA agreement	9,375	'	9,375
Ives Merger [Member]	'	'	'
Non-cash investing and financing activities:	'	'	'
Common stock issued in connection with Merger	'	'	300
Clear Image Shareholders under Short Form Merger [Member]	'	'	'
Non-cash investing and financing activities:	'	'	'
Common stock issued for acquisition of Clear Image	'	'	$3,093,948

Note_1_Basis_of_Presentation_D

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

Note 1 – Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassification

Basis of Presentation

The accompanying financial statements include the accounts of Revolutions Medical Corporation, a Nevada corporation. Unless the context otherwise requires, references to the “Company”, “RevMed”, “our”, “we”, and “us” mean Revolutions Medical Corporation.

The Company follows accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB establishes accounting principles generally accepted in the United States (“GAAP”). Rules and interpretive releases of the U.S. Securities and Exchange Commission (“SEC”) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants, which the Company is required to follow. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification (“ASC”), which serves as a single source of authoritative non-SEC accounting and reporting standards to be applied by nongovernmental entities.

Description of Business

RevMed endeavors to design, develop and commercialize auto retractable vacuum safety syringes. Our present product development effort is focused on the RevVac™ Auto Retractable Vacuum Safety Syringe (“RevVac™ Safety Syringe”), which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases. The Company also has developed a suite of proprietary Magnetic Resonance Imaging (“MRI”) software tools consisting of RevColor™, Rev3D™, and RevDisplay™. These tools are designed to enhance general diagnostic confidence through education and research use and in the future the Company believe will have specific commercial applications. The Company’s administrative facilities are located in Charleston, South Carolina and its primary manufacturing facility is located in Wuxi, China.

Since its inception in 1996, the Company has been considered a development stage enterprise for financial reporting purposes as significant efforts have been devoted to raising capital for research and development of various safety syringes and its proprietary MRI software tools. The Company began sales of its 3ml RevVac™ safety syringe in the second quarter of 2012, but has not generated sufficient recurring sales to date to not be considered a development stage company under the ASC.

Significant Accounting Policies

Cash and Cash Equivalents

The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.

Accounts Receivable

The Company records trade receivables when revenue is recognized. The Company’s allowance for doubtful accounts is primarily determined by review of specific trade receivables. Those accounts that are doubtful of collection are included in the allowance. These provisions are reviewed to determine the adequacy of the allowance for doubtful accounts. Trade receivables are charged off when there is certainty as to their being uncollectible. Trade receivables are considered delinquent when payment has not been made within contract terms.

The Company requires certain distributors to make a prepayment prior to beginning production or shipment of their order. Distributors may apply such prepayments to their outstanding invoices or pay the invoice and continue to carry forward the deposit for future orders. Such amounts are included in unearned revenue on the balance sheets. The Company records an allowance for estimated returns as a reduction to accounts receivable and gross profit. To date, returns have been immaterial.

Inventory

Inventory includes only finished goods and are valued at the lower of cost or market, with cost being determined using weighted average cost. The Company compares the average cost to the market price and records the lower value. Management considers such factors as the amount of inventory on hand and in the distribution channel, estimated time to sell such inventory, the shelf life of inventory, and current market conditions when determining excess or obsolete inventories. A reserve is established for any excess or obsolete inventories or they may be written off. For the years ended December 31, 2013 and 2012, no allowance for inventory was recorded.

Property and Equipment

Property and equipment, including significant improvements, are stated at cost. Expenditures for maintenance and repairs are charged to operating expenses as incurred. When properties are retired or otherwise disposed of, the cost of the asset and the related accumulated depreciation are removed from the accounts with the resulting gain or loss being reflected in results of operations.

Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:

Asset Category

Useful Lives

Machinery and equipment (years)

Furniture and fixtures (years)

Leasehold improvements

Shorter of leasehold improvement life or remaining term of lease

Intangibles

Intangible assets include patents and trademarks, which are valued at cost and amortized on a straight-line basis over periods varying from 17 to 20 years.

Impairment of Long-lived Assets

The Company reviews the carrying value of the long-lived assets periodically to determine if facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances exist which may indicate impairment, the Company will prepare a projection of the undiscounted cash flows of the asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.

Research and Development

Research and development costs are expensed as incurred. The Company incurred $0 and $35,544 of research and development expenses for the years ended December 31, 2013 and 2012.

Beneficial Conversion Feature

From time to time, the Company may issue convertible notes that have conversion prices that create an embedded beneficial conversion feature on the issuance date. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid-in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.

Derivative Instruments

Derivatives are measured at their fair value on the balance sheet. In determining the appropriate fair value, the Company uses the Black-Scholes-Model option pricing model (“Black-Scholes Model”). Changes in fair value are recorded in the statement of operations.

Fair Value of Financial Instruments

The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. exit price), in an orderly transaction between market participants at the measurement date. The Company categorizes its assets and liabilities measured at fair value based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are classified as follows:

●

Level 1 – quoted prices in active markets for identical assets or liabilities.

●

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

●

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at December 31, 2013, for assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Payable for indemnification

—

1,376,084

—

1,376,084

Derivative liability

—

658,453

The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Payable for indemnification

—

1,347,806

—

1,347,806

Derivative liability

—

364,802

Revenue Recognition

Revenue is recognized for sales when title and risk of ownership passes to the customer, generally upon shipment from the manufacturing facility in Wuxi, China or from our warehouse facility in Ladson, South Carolina; when the price is fixed or determinable; and when collection is reasonably assured.

Share-based Compensation

The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes Model and value of common shares based on the trading price on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.

Income Taxes

The Company uses the liability method of accounting for income taxes. Under the liability method, deferred taxes are determined based on the differences between the financial statement and tax basis of assets and liabilities at enacted tax rates in effect in the years in which the differences are expected to reverse.

Earnings (Loss) Per Common Share

Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income per common share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net loss per common share. For the year ended December 31, 2013, potentially issuable shares, including options and warrants to purchase 11,749,008 shares of the Company’s common stock and notes payable convertible to 52,530,562 shares of the Company’s common stock have been excluded from the calculation. For the year ended December 31, 2012, potentially issuable shares, including options and warrants to purchase 14,980,000 shares of the Company’s common stock and notes payable convertible to 6,603,582 shares of the Company’s common stock have been excluded from the calculation.

Subsequent Events

The Company has evaluated all transactions occurring between the end of its fiscal year, December 31, 2013, through the date of issuance of the financial statements for subsequent event disclosure consideration.

Critical Accounting Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.

Reclassifications

Certain prior period amounts have been reclassified to conform to current period presentation.

New and Pending Accounting Standards

The Company does not anticipate that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company. In addition, the Company is evaluating other accounting standards and exposure drafts, such as exposure drafts related to revenue recognition, leases and fair value measurements, that have been issued or proposed by the FASB or other standard setting bodies that do not require adoption until a future date to determine whether adoption will have a material impact on the Company’s financial statements.

Note_2_Going_Concern

Note 2 - Going Concern	12 Months Ended
Note 2 - Going Concern	Dec. 31, 2013
Going Concern [Abstract]	'
Going Concern [Text Block]	'
	Note 2 – Going Concern

	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has not established significant sources of revenue to fund the development of its business and pay operating expenses, resulting in a cumulative net loss of $44,363,260 for the period from inception (August 16, 1996) to December 31, 2013 and a working capital deficit of $7,642,006 at December 31, 2013. The ability of the Company to continue as a going concern during the next year depends on successful sales of its RevVac™ Safety Syringe and completion of the Company’s capital raising efforts to fund the development of its 1ml, 5ml and 10ml auto-retractable vacuum safety syringes. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note_3_Property_And_Equipment

Note 3 - Property And Equipment	12 Months Ended
Note 3 - Property And Equipment	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 3 – Property and Equipment

	Property and equipment consisted of the following:

		December 31,
		2013			2012

	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(176,193	)		(89,726	)
		$	270,189		$	356,656

	For 2013 and 2012, the Company recognized depreciation and amortization expense related to property and equipment of $86,467 and $69,008, respectively.

	During 2012, the Company impaired $710,000 of the $760,000 production mold payments made to Medical Investment Group, Inc. (“MIG”) in 2011 and wrote off an $80,000 prepayment to MIG. The impairment charge was based upon the arbitration hearing against MIG in November, 2012. The hearing and the final ruling made clear that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault, a representative of MIG, for other non-production related purposes. The American Arbitration Association panel ruled that the only assets in which production was funded by MIG from the Company’s production payments were $50,000 in trial molds. The arbitration panel ruled that a total of $770,000 awarded to the Company. The Company has not received such payment to date. Any gain related to this award will be recorded when collected.

	During 2012, the Company also impaired $50,000 for a trial mold that is no longer considered useful to the Company.

Note_4_Intangibles

Note 4 - Intangibles	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	Note 4 – Intangibles

	Intangibles consisted of the following:

		December 31,
		2013			2012
	Patent	$	184,906		$	146,538
	Less accumulated amortization		(51,389	)		(39,851	)
		$	133,517		$	106,687

	The Company own one US patent on its vacuum safety blood drawing device issued in 2003. The Company owns two US patents on its RevVac™ auto retractable vacuum safety syringe, the first issued in January 2005 and the second issued in January 2009 (see Note 10). The RevVac™ auto retractable vacuum safety syringe has international patents issued in China, Japan, and Mexico, and are pending issuance in Australia, Canada, Taiwan, and the European Union. The Company filed US and international Patent Cooperation Treaty provisional patents on vacuum auto retraction designs for a prefilled safety syringe in 2011 and 2012, respectively. In 2013, the Company has decided not to pursue the issuance of its imaging segmentation software patents as written but has made improvements to the software technology and intends to file new provisional patents and copyright protection on these software improvements in the future.

	During the year ended December 31, 2012, the Company impaired the cost of $15,000 licensing agreement which provided licensing rights to a Traxis biopsy software product because the Company decided not to pursue this technology.

	For 2013 and 2012, the Company recognized amortization expense of $11,538 and $33,963, respectively.

Note_5_Accounts_Payable_and_Ac

Note 5 - Accounts Payable and Accrued Liabilities	12 Months Ended
Note 5 - Accounts Payable and Accrued Liabilities	Dec. 31, 2013
Note 5 - Accounts Payable and Accrued Liabilities [Line Items]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 5 – Accounts Payable and Accrued Liabilities

	Accounts payable and accrued liabilities consisted of the following:

		December 31,
		2013		2012
	Accounts payable	$	565,127	$	432,436
	Accrued payroll liabilities and related penalties		607,134		411,670
	Accrued salary		418,440		143,167
	Accrued interest		158,869		134,559
	Other accruals		117,622		539
		$	1,867,192	$	1,122,371

	As of December 31, 2013 and 2012, the Company accrued $607,134 and $411,670, respectively, pursuant to state and federal payroll tax liabilities and related penalties. Although the Company plans to settle these amounts, there is no assurance that its efforts to settle will be successful. Tax liens in the aggregate amount of $6,164 were filed against the Company as of December 31, 2013 by the South Carolina Department of Revenue due to these delinquent payments and failure to file the required tax forms. Action by federal taxing authorities has not been initiated or threatened at this point. There is no assurance, however, that such action will not be initiated in the future. In October 2013, the Company obtained representation and is negotiating with the taxing authorities to resolve these liabilities.
Yeso Med [Member]	'
Note 5 - Accounts Payable and Accrued Liabilities [Line Items]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 6 – Payable to Yeso-med

	On December 1, 2011, the Company entered into a 5-year agreement with Wuxi Yushou Medical Appliance Co., Ltd (“Yeso-med”). Pursuant to the agreement, commencing from the date that Yeso-med demonstrates to the Company’s satisfaction that it has the capacity to commence regular production of the syringes in the 3ml size in the minimum amount of at least 2,500,000 units per month, the Company will place orders of at least 2,500,000 units per month for the term of this agreement. If the Company does not place with Yeso-med the minimum order for a single month, Yeso-med shall have the right to receive payments from the Company equal to 50% of the supply price of each unit below the minimum order amount required for that month. The Company has the right to have the amount paid under this requirement to serve as payment against future orders provided the quantity ordered exceeds the minimum quantity for that month. In July 2012, Yeso-med met the capacity requirement. However, the Company has not yet placed an order as of December 31, 2013. As of December 31, 2013 and 2012, a payable was recorded to Yeso-med related to this minimum purchase requirement of $2,749,075 and $783,593, respectively. For 2013 and 2012, $1,965,482 and $783,593 was recorded as a loss on firm purchase commitments, respectively.

	The payable to Yeso-med also included amounts due for product purchased of $208,501 and $208,258 as of December 31, 2013 and 2012, respectively, and amounts due for equipment purchased of $289,519 and $289,009 as of December 31, 2013 and 2012, respectively.

Note_7_Payable_for_Indemnifica

Note 7 - Payable for Indemnification (Payable for Indemnification [Member])	12 Months Ended
	Dec. 31, 2013
Payable for Indemnification [Member]	'
Note 7 - Payable for Indemnification [Line Items]	'
Short-term Debt [Text Block]	'
	Note 7 – Payable for Indemnification

	On February 5, 2009, the Company entered into an Indemnification Settlement Agreement with Gifford M. Mabie, founder and former Chief Executive Officer of the Company. Pursuant to the agreement, the Company agreed to indemnify Mr. Mabie for the payment of penalties, prejudgment interest and post-judgment interest to the SEC that is part of the Final Judgment, dated March 11, 2005, in SEC v. Maxxon, Inc., Gifford M. Mabie, Jr., Thomas R. Coughlin, Jr. 02-CV-975-H(J) which resulted from actions taken in good faith by Messrs. Mabie and Coughlin in the performance of duties as an officer and directors of the Company. The payment amount stated in the Final Judgment was $1,088,067.

	The agreement specifies that the Company is to periodically issue shares of its common stock to a special account for Mr. Mabie so that shares can be sold each day the market is open until the liability is satisfied. The special account was initially funded by common stock owned by Mr. Mabie. The total number of shares sold from the special account is limited to 5% of the total trading volume each day. A percentage equal to Mr. Mabie’s federal and state tax liabilities up to a maximum of 40% will be retained by the brokerage firm administering the special account and remitted to the Internal Revenue Service and to the Oklahoma Tax Commission or the tax commission having jurisdiction in the state in which Mr. Mabie resides. In the event that Mr. Mabie is entitled to a tax refund, the refund will be remitted to the SEC.

	On December 14, 2010, the Company issued 400,000 shares of the Company’s common stock, initially valued at $184,000, to the special account. An additional 400,000 shares were issued to the special account on March 15, 2012 with a value of $140,560 determined based upon the 10-day average share price prior to the date of issuance. At each reporting date, the Company revalues the shares held in the special account and adjusts the outstanding balance. Net increases and decreases in the value of the Company’s common shares held in the special account are recorded in the current period statement of operations. As of December 31, 2013 and 2012, the remaining principal balance, including the estimated taxes, to be paid was $1.4 million and $1.3 million, respectively, based upon the Company’s valuation of the stock. For 2013 and 2012, the net loss related to shares of the Company’s common stock held in the special account was $28,278 and $63,347, respectively. As of December 31, 2013, there were 301,463 shares of the Company’s common stock held in the special account.

Note_8_Convertible_Notes

Note 8 - Convertible Notes	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 8 – Convertible Notes

	Convertible notes consisted of the following:

		December 31,
		2013			2012
	Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014	$	191,663		$	191,663
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on March 21, 2013, fully converted in 2013		-			7,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 10, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on August 27, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 19, 2014		35,000			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on July 23, 2014		42,500			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on September 12, 2014		47,500			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on June 30, 2014		32,500			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on July 29, 2014		10,000			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on August 29, 2014		17,500			-
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due on January 3, 2013		-			62,165
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due monthly until April 26, 2014		189,844			-
	Convertible Promissory Notes Payable issued in the course of a private placement to individual, unsecured, interest rate of 12% per annum, with payment due on April 9, 2014 or subsequently on demand by holder		140,862
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on September 3, 2014		35,000			-
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on January 26, 2014		75,000			100,000
			817,369			446,328
	Less: debt discount		(247,661	)		(229,573	)
		$	569,708		$	216,755

	JMJ Financial

	On February 22, 2011, the Company issued a convertible promissory note in the amount of $1,050,000 to JMJ Financial, Inc. (“JMJ”). The note bears interest in the form of a one-time interest charge of 8%, payable with the note’s principal amount on the maturity date, February 22, 2014. The note is convertible to the Company’s common stock at a price equal to 70% of the average of the three lowest closing market prices of the Company’s common stock for the 20 trading days prior to the conversion date. In connection with the note, the Company entered into a registration rights agreement with JMJ to provide JMJ registration rights for common shares underlying this note. The note will only be funded when the conversion price calculated on each payment date is equal to or greater than $0.015 per share and there are sufficient shares remaining in the registration statement. During 2012, JMJ converted $15,498 under this agreement into 180,000 shares of the Company’s common stock. The principal amount owed to JMJ at December 31, 2013 and 2012 was $191,663 under the convertible promissory note. The Company analyzed the JMJ note for derivative accounting consideration and determined that the note qualifies for accounting treatment as a financial derivative and recorded an initial discount of $450,000 on the issuance date. For 2013 and 2012, the Company recorded $95,462 and $80,000 of interest expense related to the amortization of the debt discount. At December 31, 2013 and 2012, there was $11,229 and $106,691, respectively, of unamortized debt discount related to the JMJ notes.

	The Company is currently in litigation with JMJ. See Note 10.

	Asher Enterprises

	On March 4, August 15, October 21, and December 10, 2013, the Company issued convertible promissory notes to Asher Enterprises for proceeds of $42,500, $35,000, $42,500 and $47,500 in cash, respectively (the “2013 Asher Notes”). The notes are convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest three trading prices for the Company’s common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date and (2) a fixed conversion price of $0.00009 per share in the case of the notes issued on March 4 and August 15, 2013 and $0.00005 in the case of the notes issued on October 21 and December 10, 2013.

	The March 4 note has a beneficial conversion feature discount of $42,500, all of which was amortized as interest expense for 2013. The Company analyzed the August 15, October 21 and December 10, 2013 notes for derivative accounting consideration and determined that the conversion feature of these notes qualify for accounting treatment as a financial derivative. The conversion features of these notes were valued at an aggregate amount of $266,925 on the issuance date. As a result, the notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the notes in the aggregate amount of $141,925 was expensed immediately as additional interest expense. For 2013, the Company recognized $30,514 of aggregate interest expense related to the amortization of the debt discount. At December 31, 2013, there was $94,486 of unamortized discount related to August 15, October 21 and December 19, 2013 notes. For 2013, the Company also recorded interest expense of $66,930 related to the amortization of debt discount on notes issued in 2012 to Asher Enterprises.

	During 2013, Asher Enterprises converted principal of $92,500 with accrued interest related to notes issued in 2012 into 2,726,118 shares of the Company’s common stock. In addition, during 2013, Asher Enterprises converted principal of $42,500 with accrued interest related to the note issued on February 28, 2013 into 4,857,358 shares of the Company’s common stock.

	Carebourn Capital

	On March 19, October 31, November 27 and December 24, 2013, the Company issued a convertible promissory note to Carebourn Capital for proceeds of $60,000, $32,500, $10,000 and $17,500 in cash, respectively, (“2013 Carebourn Notes”). The March 19, 2013 note is convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest three trading prices for the Company’s common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date (2) a fixed conversion price of $0.00009 per share. The remaining notes issued in 2013 are convertible to the Company’s common stock only at the variable conversion price noted above.

	The Company analyzed the conversion feature of the March 19, 2013 not for derivative accounting consideration and determined that the conversion feature for this note does not qualify for accounting treatment as a financial derivative. The March 19, 2013 note has a beneficial conversion feature discount of $49,091, all of which was amortized as interest expense for 2013. The Company analyzed the October 31, November 27 and December 24, 2013 notes for derivative accounting consideration and determined that the conversion feature of these notes qualify for accounting treatment as a financial derivative. The conversion features of these notes were valued at an aggregate amount of $115,642 on the issuance date. As a result, the notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the notes in the aggregate amount of $55,642 was expensed immediately as additional interest expense. For 2013, the Company recognized $14,736 of aggregate interest expense related to the amortization of the debt discount. At December 31, 2013, there was $45,264 of unamortized discount related to the October 31, November 27 and December 24, 2013 Notes. During 2013, Carebourn Capital converted principal of $60,000 with accrued interest related to March 19, 2013 note into 3,779,454 shares of the Company’s common stock.

	TCA Global Credit Master Fund, LP

	2012 TCA Securities Purchase Agreement

	On January 3, 2012, the Company entered into a securities purchase agreement with TCA Global Credit Master Fund, LP (“TCA”) pursuant to which TCA would purchase up to $2,000,000 of the Company’s common stock. The Company agreed to pay a $100,000 facility fee by issuing to TCA a number of the Company’s common shares (“facility shares”). To determine the number of shares issuable to TCA for the facility fee, the Company’s common stock was valued at a volume weighted average price at January 2, 2012. The facility shares should be adjusted nine months after January 2, 2012 by the volume weighted average prices of the Company’s common stock five trading days prior to the revaluation date. The Company issued 559,268 common shares in 2012 to TCA which satisfied $51,924 of the facility fee upon revaluation. On August 13, 2012, the Company and TCA agreed to terminate the committed equity financing agreement based on the Company’s failure to achieve bulletin board listing as required under the agreement.

	In connection with the securities purchase agreement with TCA, the Company issued a convertible promissory note to TCA for a principal amount of $225,000 (“TCA Note”). The note bears interest at a rate of 12% per annum and provides for the payment of all principal and interest 12 months from the date of the note’s issuance. The conversion price was determined by multiplying 95% by the average of the two lowest daily volume weighted average prices of the Company’s common stock on the OTC Markets during the five business days immediately preceding the date of conversion. The Company analyzed the TCA Note for derivative accounting consideration and determined that the TCA Note qualifies for accounting treatment as a financial derivative. The conversion feature of the TCA Note was valued at $174,448 on the issuance date and recorded as debt discount which was fully amortized in 2012.

	TCA converted principal of $27,840 into 300,000 shares of the Company’s common stock on January 3, 2013. On May 9, 2013, 1,750,000 shares (“Past Due Shares”), valued at $140,000, were issued to TCA to settle all outstanding liabilities related to the January 2, 2012 security purchase agreement which totaled $106,987. The Company recorded a $33,013 loss on extinguishment of debt related to the settlement. There is a leak out provision provided in this settlement. TCA shall return all remaining shares back to the Company once proceeds of the sale of shares from the 1,750,000 shares issued reach $80,000. The Company will pay cash or issue additional shares to TCA if all shares issued on May 9, 2013 are sold and total net proceeds do not reach $80,000. The Company has the right to redeem any Past Due Shares then in TCA’s possession for an amount equal to the $80,000 less any net proceeds received by TCA from the sales of the Past Due Shares before March 26, 2014. In the event that TCA has not collected net proceeds equal to $80,000 from the sale of Past Due Shares on March 26, 2014, then at any time after, TCA shall have the right to require that the Company redeem by cash all Past Due Shares for the amount equal to $80,000 less any net proceeds received by TCA from sales of the Past Due Shares. At December 31, 2013, TCA had sold 638,175 shares and collected $28,122 net proceeds. Accordingly, the Company accrued an additional expense of $29,642 which equals the difference between the $80,000 and the fair market value of the remaining 1,111,825 shares at December 31, 2013 of $0.02 per share.

	2013 TCA Securities Purchase Agreement

	On April 26, 2013, the Company entered into a securities purchase agreement with TCA, pursuant to which, TCA shall purchase from the Company up to $2,000,000 of senior secured convertible redeemable debentures (the “Debentures”). The Debentures will be purchased in a series of closings and pursuant to the first such closing, TCA purchased that certain senior convertible redeemable debenture in the amount of $250,000.

	The Debentures were issued at 7% original issue discount and the discount of $17,500 is amortized over one year, the term of the Debentures, using the straight-line method which approximates the effective interest method due to the short term nature of the note. The note bears interest at a rate of 12% per annum and the Company shall make monthly payments of principal and interest commencing on May 26, 2013 with the first two payments only including interest. During 2013, the Company made principal payments of $77,656 and interest payments of $11,781 to TCA. As of December 31, 2013, the Company was not in compliance with the financial covenants of this credit facility as it was unable to make the scheduled principal and interest payments for the last two months of 2013. On February 24, 2014, TCA filed in a Florida court to seek unpaid monthly payments, default interest and penalties related to this facility as part of the credit facility agreement. The Company became delinquent on payments and was notified of default on January 24, 2014. The Company is working with TCA on an amicable payment of past due amounts and seeks to pay the amount left owed to TCA after it receives disbursements from legal settlements, issuance of additional shares, and or proceeds from anticipated sales.

	The Debentures are convertible at a price determined by multiplying 85% of the average daily volume weighted average price of the Company’s common stock during the five business days immediately preceding the date of conversion. The Company analyzed the Debentures for derivative accounting consideration and determined that the Debentures qualify for accounting treatment as a financial derivative. The conversion feature of the Debentures was valued at $218,053 on the issuance date and recorded as debt discount. As of December 31, 2013, there was $53,859 of unamortized debt discount related to the Debentures.

The Company also issued to TCA 9,375,000 shares, which were pledged as security for the securities purchase agreement and was held with an escrow agent until such time as the full payment and performance of all of the obligations of the Company have been satisfied in accordance with the terms of the agreement. The Company also granted TCA the right to vote and receive dividends during the period the 9,375,000 shares were held by TCA. The Company recorded shares issued at par value of $9,375 with an offset to additional paid-in capital.

On May 9, 2013, the Company issued 2,000,000 restricted shares to pay for the $100,000 facility fee pursuant to the 2013 TCA securities purchase agreement entered into on April 26, 2013 with TCA. TCA will return all remaining shares to the Company if total net proceeds of $100,000 are reached. The Company will pay cash or issue additional shares if a total of 2,000,000 shares are sold and net proceeds do not total $100,000. The Company has the right to redeem any shares then in TCA’s possession for an amount equal to the $100,000 facility fee less any net proceeds received by TCA from the sales of the Company’s shares. On the issuance date, the Company recorded an expense of $160,000 for the issuance of 2,000,000 shares based on the stock price. At December 31, 2013, TCA had not sold any of the 2,000,000 shares. Accordingly, the Company accrued an additional expense of $60,000 which represents the difference between the $100,000 facility fee and the fair market value of the 2,000,000 shares at December 31, 2013 of $0.02 per share.

2012 Individual Convertible Notes Payable

During 2012, the Company issued 22 convertible notes payable to individuals for proceeds of $956,501 in cash (“Individual Convertible Notes”). The Individual Convertible Notes matured one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity.

The principal amount of the Individual Convertible Notes and accrued interest are convertible into the Company’s common stock at a conversion price equal to 75% of the average of the daily volume weighted average prices of the Company's Common Stock during the five trading days immediately prior to the conversion date, provided that in no event, shall the note holders convert any portion of the Individual Convertible Notes when the sum of (1) the number of shares of common stock beneficially owned by the holder and its affiliates and (2) the number of shares of common stock issuable upon conversion would result in beneficial ownership by the holder and its affiliates of more than 4.99% of the Company’s outstanding common shares. During 2013, $25,000 of the Individual Convertible Notes with accrued interest was converted into 353,727 shares of the Company’s common stock. As of December 31, 2013 and 2012, Individual Convertible Notes included principal of $75,000 payable to Vincent Olmo, the Company’s COO, with a debt discount of $0 and $42,534, respectively. This note was extended through May 26, 2014.

In connection with the issuance of the Individual Convertible Notes, warrants to purchase 3,826,005 shares of the Company’s common stock at $0.25 per share (“$0.25 Warrant”) and warrants to purchase 1,913,003 shares of the Company’s common stock at $0.50 per share (“$0.50 Warrant”) were issued to investors. The warrants have a term of less than one year and expire during the period beginning December 31, 2012 and ending June 30, 2013.

Of the $956,501 proceeds received from the Individual Convertible Notes, $347,097 was allocated to the warrants based on a grant date fair value of $589,416 calculated using the Black-Scholes Model with the following assumptions: (1) 3.9% risk-free discount rate, (2) expected volatility of 155.60 ~218.64%, (3) $0 expected dividends, and (4) an expected term of 0.3~1 years based on the term of warrant.

On March 1, 2013, the Company extended the expiration date of the $0.25 Warrants to June 30, 2013 and the $0.50 Warrants to September 30, 2013. Warrants to purchase 2,859,008 shares of the Company’s common stock that originally expired on December 31, 2012 were reissued to the note holders. The Company recorded a $148,127 modification expense related to the extension.

On August 28, 2013, the Company further extended the expiration date of the $0.25 Warrants to June 30, 2014 and the $0.50 Warrants to September 30, 2014. The Company recorded a $40,501 modification expense related to the extension.

On November 20, 2013, the Company reduced the exercise price of the $0.25 Warrants to $0.125 and the exercise price of the $0.50 Warrants to $0.25. The Company recorded a $21,745 modification expense related to the change.

The Company analyzed the Individual Convertible Notes for derivative accounting consideration and determined that the conversion feature of the Individual Convertible Notes qualify for accounting treatment as a financial derivative. The conversion feature of Individual Convertible Notes was valued at $777,766 on the issuance date. As a result, some of the Individual Convertible Notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the Individual Convertible Notes of $182,733 was expensed immediately as additional interest expense. For the years ended December 31, 2013 and 2012, the Company recognized $42,534 and $885,418 of interest expense related to the amortization of the debt discount. At December 31, 2013 and 2012, there was $0 and $55,952 of unamortized discount related to the Individual Convertible Notes, respectively.

2013 Individual Convertible Notes Payable

On April 25, 2013, the Company issued a $50,000 convertible note to an individual together with warrants to purchase 200,000 shares of the Company’s common stock at $0.25 per share and 100,000 shares of the Company’s common stock at $0.50 per share. These warrants were valued at $3,526, calculated using the Black-Scholes Model. The individual investor converted the $50,000 convertible promissory note into 1,000,000 shares of the Company’s common stock on the same day the note was issued.

On September 3, 2013, the Company issued a $35,000 convertible note to an individual. The note matures one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity. The conversion provisions of this note are the same as the 2012 Individual Convertible Notes as described above. The Company analyzed the note for derivative accounting consideration and determined that the conversion feature of the note qualifies for accounting treatment as a financial derivative. The conversion feature of this note was valued at $37,837 on the issuance date. As a result, the note was fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the note of $2,837 was expensed immediately as additional interest expense. For 2013, the Company recognized $11,602 of interest expense related to the amortization of the debt discount. At December 31, 2013, there was $23,398 of unamortized discount related to the note. In connection with the issuance of the note, warrants to purchase 140,000 shares of the Company’s common stock at $0.25 per share and 70,000 shares of the Company’s common stock at $0.50 per share were issued to the note holder. These warrants were valued at $2,588 using the Black-Scholes Model.

On October 9, 2013, the Company issued six convertible notes in an aggregate amount of $140,862 to an individual to settle amounts owed by the Company for legal services rendered to the Company. The notes are callable at any time by the holder subsequent to the six month anniversary of the issuance date. Interest accrues at the rate of 12% per year on the outstanding principal amount to be paid at maturity. The principal amount of the note and accrued interest are convertible into the Company’s common stock at a conversion price equal to the average five trading day closing price of the Company’s common stock during the five trading days immediately prior to the conversion date multiplied by two, provided that in no event, shall the note holder convert any portion of these notes when the sum of (1) the number of shares of common stock beneficially owned by the holder and its affiliates and (2) the number of shares of common stock issuable upon conversion would result in beneficial ownership by the holder and its affiliates of more than 4.99% of the Company’s outstanding common shares. The Company analyzed the notes for derivative accounting consideration and determined that the conversion feature of the notes qualifies for accounting treatment as a financial derivative. The conversion feature of the notes was valued at an aggregate amount of $35,709 on the issuance date. For 2013, the Company recognized $16,285 of interest expense related to the amortization of the debt discount. At December 31, 2013, there was $19,424 of unamortized discount related to the notes. The Company has determined that it has grounds to dispute the amounts owed to the individual for legal services rendered represented by the aggregate principal amount of the notes.

Note_9_Derivatives_Note_Conver

Note 9 - Derivatives - Note Conversion Feature (Note Conversion Feature [Member])	12 Months Ended
	Dec. 31, 2013
Note Conversion Feature [Member]	'
Note 9 - Derivatives - Note Conversion Feature [Line Items]	'
Derivatives and Fair Value [Text Block]	'
	Note 9 – Derivatives – Note Conversion Feature

	Due to the conversion feature contained in some of the notes the Company issued, the actual number of shares of common stock that would be required if a conversion of the notes was made through the issuance of the Company’s common stock cannot be predicted, and the Company could be required to issue an amount of shares that may cause it to exceed its authorized share amount. As a result, the conversion feature requires derivative accounting treatment and will be bifurcated from the note and “marked to market” each reporting period through the income statement. The fair value of the conversion feature of these notes was recognized as a derivative liability instrument and will be measured at fair value at each reporting period. In determining the fair value, the Company uses the Black-Scholes Model. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes Model.

	The following is a summary of the activity of the derivative liability for 2013:

	Fair value at December 31, 2011	$	442,311
	Decrease in value		(131,397	)
	Addition		952,214
	Reclassification from liability to equity as a result of note conversions and repayment		(898,326	)
	Fair value at December 31, 2012		364,802
	Decrease in value		(304,994	)
	Addition		674,167
	Reclassification from liability to equity as a result of note conversions and repayment		(75,522	)
	Fair value at December 31, 2013	$	658,453

	The derivative liability was valued using the Black-Scholes Model with the following assumptions:

		December 31,
		2013					2012
	Risk free interest rate			0.13		%		0.11%	to	0.16	%
	Expected life (years)		0.07	to	0.7			0.01	to	2.1
	Dividend Yield			0		%			0		%
	Volatility		256%	to	394	%		130%	to	219	%

		Variant issuance date during years ended December 31,
		2013					2012
	Risk free interest rate		0.10	to	0.15	%		0.1	to	0.12	%
	Expected life (years)		0.5	to	0.99			0.23	to	2.1
	Dividend Yield			0		%			0		%
	Volatility		213%	to	293	%		130%	to	156	%

Note_10_Commitments_and_Contin

Note 10 - Commitments and Contingencies	12 Months Ended
Note 10 - Commitments and Contingencies	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 10 – Commitments and Contingencies

	KVM Capital Partners Investment Agreement

	On June 11, 2013, the Company entered into an Investment Agreement (the “Investment Agreement”) with KVM Capital Partners (“KVM”), whereby the parties also agreed to enter into a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the terms of the Investment Agreement, for a period of 36 months commencing on the trading day immediately following date of effectiveness of the Registration Statement, KVM will commit to purchase up to $1,500,000 of the Company’s common stock, pursuant to a notice from the Company (“Puts”), covering the Registrable Securities (as defined below). The purchase price of the Shares under the Investment Agreement is equal to a 22.5% percent discount to the average of the three lowest closing bids during the last seven trading days after the Company delivers to KVM a Put notice in writing requiring KVM to purchase shares of the Company, subject to the terms of the Investment Agreement.

	The Registrable Securities include (1) shares of the Company’s common stock and (2) any shares of capital stock issued or issuable with respect to the Company’s common stock, if any, as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, which have not been (1) included in the Registration Statement that has been declared effective by the SEC, or (2) sold under circumstances meeting all of the applicable conditions of Rule 144 (or any similar provision then in force) under the 1933 Act.

	As further consideration for KVM entering into and structuring the Investment Agreement, the Company paid to KVM a $10,000 fee by issuing to KVM 250,000 restricted shares of its common stock on June 11, 2013. As of December 31, 2013, the Company has not filed a Registration Statement and, accordingly, has no availability under this agreement.

	Maxxon/Globe Joint Venture Agreement

	In September 2005, the Company filed a patent on its RevVac™ Safety Syringe with Globe Med Tech which gave a 50% ownership of this patent to the Company and 50% to Globe Med Tech. On November 3, 2005, the Company (f.k.a. Maxxon, Inc.,) and Globe Med Tech, Inc. (“Globe”) entered into a definitive joint venture agreement (the “Joint Venture Agreement”) to patent, develop, manufacture, market and distribute safety needle products throughout the world. The Company and Globe each owned 50% of the joint venture. The Company contributed its safety syringe technology and patent rights related thereto and Globe contributed its safety syringe IV catheter and patent rights related thereto. In connection with the Joint Venture Agreement, the Company issued restricted shares of its common stock, valued at $625,066, to Globe. Subsequent to December 31, 2006, the Company ended the Joint Venture Agreement and cancelled the restricted shares of common stock that were issued to Globe pursuant to the agreement. The above noted patent was issued on January 13, 2009.

	On March 1, 2007, the Company filed a lawsuit in the District Court of Tulsa County, Oklahoma against Globe to rescind, terminate and seek monetary damages for the non-fulfillment and breach of the Joint Venture Agreement, and other related agreements, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements. On October 29, 2008, the Company filed in the District Court of Harris County, Texas, a lawsuit for fraud and contempt of court for Globe and Andy Hu, individually. On October 21, 2011, the Company was granted its request for summary judgment against Globe and awarded $311,440 and the return of 266,666 shares of the Company’s common stock by a Federal District Court in Tulsa County, Oklahoma. In addition to the monetary award and the return of the Company’s common stock, Globe is also required to return all syringes, design files, and sample molds to the Company. Furthermore, the Court ordered that Globe assign to the Company all rights to the patent issued on January 13, 2009 for the RevVac™ Safety Syringe. Globe is prohibited from claiming any interest or ownership in the Company’s safety vacuum syringes going forward.

	On April 30, 2013, the Company exercised its legal rights under a writ of execution in Harris County, Texas, pursuant to which the Company seized all valuable property from Globe Med Tech’s office including 266,666 restricted shares of common stock of Revolutions Medical, all design and patent files relating to its auto retractable vacuum safety syringe, furniture, computers, phones and other office equipment and information. Globe’s web hosting company has been notified and ordered under the judgment and writ of execution to shut down Globe’s website until all information and references of ownership, patents and awards regarding the RevVac™ Safety Syringe are removed from the website. The Company will continue to use all available legal means under the judgment until all monies are collected and the judgment is satisfied in full. On August 27, 2013, the Company cancelled the 266,666 shares.

	MIG and SPD

	On September 26, 2012, the Company filed suit in South Carolina Federal District Court against Strategic Product Development ("SPD"), Richard H. Theriault, Vita S. Theriault, Darius R. Theriault, Raminta Theriault, Goddard Technologies, Inc. ("GTI") and others, claiming that the defendants purposely and materially misled and misrepresented capabilities and progress on a variety of initiatives related to the development and manufacture of the Company's RevVac™ Safety Syringe to officers and directors of Revolutions Medical, which caused a delay in its production of approximately one year. The suit further alleges that Richard H. Theriault and other defendants defrauded the Company and misappropriated funds in violation of the United States' Racketeer Influenced and Corrupt Organizations Act and that GTI improperly assigned certain rights to the Company's new provisional patents to SPD without authorization. In February, 2013 the Company changed the venue to the United States District Court of Massachusetts against GTI. On February 17, 2014, the Company amended its claims against GTI and certain employees at Goddard to include negligence and unfair trade practices both in the state of MA and in SC based upon supplemental discovery provided by Goddard’s attorney. Depositions and the jury trial are being scheduled for the second quarter of 2014.

	On January 2, 2013, the Company won its arbitration proceeding concerning its counter claims against Richard Theriault, former manufacturer, Medical Investment Group (“MIG”) and former consultant, SPD. The monetary award included $770,000 in recoupment of production costs plus interest, legal fees and other arbitration costs, which will total approximately $1 million. In other claims, Theriault was found guilty of fraud in the inducement and breach of contract and was found to have no rights to any of the Company's proprietary technology, files, drawings, designs, patents or products. A panel of the American Arbitration Association (“Arbitrator”) determined that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault for other non-production related purposes. The Arbitrator ruled that the only assets in which production was funded by MIG from the Company’s production payments were $10,000 in trial molds. The equipment asset on the balance sheet was reduced by $710,000 and charged to impairment of assets in 2012 as the payments were not associated with a production or trial mold. The $770,000 award is for the recovery of damages related to these production payments. The gain related to this award will be recorded when collected. The Company has retained counsel in Massachusetts and South Carolina to assist in efforts to collect these damages.

	On February 2, 2013, Richard H. Theriault, MIG, SPD, and other Theriault corporate entities, filed for bankruptcy in Massachusetts under Chapter 11. The South Carolina lawsuit has been temporarily stayed. On March 13, 2013, United States Federal District Court in Massachusetts granted an injunction against Richard H. Theriault and MIG, enjoining and restraining them from transferring or alienating any assets in their possession without approval from the Court. On May 6, 2013, that court upheld its ruling in favor of continuing the injunction. On September 17, 2013 the bankruptcy court allowed the Company to lift the stay to confirm the arbitration judgment in South Carolina. The Company continues to pursue all of its rights in the Theriault bankruptcy. Theriault and MIG have recently filed a settlement proposal and plan with the bankruptcy court for approval by all creditors and a hearing is scheduled on May 7, 2014. The Company has accepted from Theriault and MIG $125,000 in a cash disbursement and $320,000 in annuity payments over 4 years along with other considerations and awaits confirmation at the hearing. The Company continues to preserve all of its legal rights against SPD.

	Thomas G. O’Brien

	On October 1, 2012, the Company filed suit in South Carolina Federal District Court against its former President and Director, Thomas G. O'Brien (“O’Brien”), alleging that O'Brien, as a director and officer of the Company, committed fraud, disregarded his fiduciary duties, and breached other obligations owed to the Company and its shareholders, by facilitating and negotiating contracts on behalf of the Company while at the same time sharing confidential Company information with, and receiving bribes from, Richard H. Theriault, SPD, and Medical Investment Group, (MIG). The complaint seeks to recover actual and punitive damages as well as a return of all salary paid to O'Brien under his employment agreement and over 3 million restricted shares. On January 17, 2013, the South Carolina lawsuit was dismissed without prejudice, so the Company can pursue all of its claims against Thomas G. O'Brien in arbitration. No arbitration case is presently pending between the Company and O’Brien.

	JMJ Financial, Inc.

	A lawsuit was filed against the Company by Justin Keener d/b/a JMJ Financial (“JMJ”) in Miami-Dade County, Florida on March 15, 2012. The lawsuit claims that the Company breached the terms of the convertible debt agreement by failing to issue shares requested in a stock conversion by JMJ on January 9, 2012 for 1,000,000 shares and on January 30, 2012 for 1,226,049 shares. JMJ is seeking the delivery of 2,226,049 shares of common stock of the Company, plus costs and prejudgment interest. On August 30, 2012, the Company filed its counterclaims against JMJ, which included fraud by concealment, among other claims. The Company alleges that JMJ had a responsibility and obligation under Florida law to disclose during the negotiations of the agreement the fact that Keener and JMJ had outstanding and current issues with these type of convertible notes with DTC which could do detrimental harm to liquidity and electronic transfer of the Company's stock if DTC eligibility was “chilled”. In the securities trading industry, the loss of eligibility for electronic trading, transfer, and delivery of common stock is known as a “chill”. This would severely hamper future capital raising and harm its current shareholders but would solely benefit Keener and JMJ under the default clauses in this agreement. On March 14, 2013 the Company did receive a letter from the DTC advising that a “chill” was placed on its stock. All of the JMJ share issuances were among the share issuances that the DTC identified to be reviewed. In July 2013, the Company won its motion to compel discovery from JMJ and Keener to provide all documents related to all financings with public companies that Keener and JMJ were involved, especially companies that DTC put a "chill" on their publicly traded stock and any regulatory actions or rulings against Keener and JMJ. On October 14, 2013, the DTC advised the Company that the “chill” had been lifted. If a positive settlement cannot be negotiated, the Company plans on bringing their counterclaims in a jury trial court proceeding.

	SEC

	On September 20, 2012, the Securities and Exchange Commission (“SEC”) filed a civil complaint in Federal District Court in Georgia against the Company and Rondald L. Wheet, the Company’s current Chief Executive Officer, alleging that between approximately August 2010 and July 2011, the Company and its Chief Executive Officer issued a series of misleading press releases that contained statements designed to convey the impression that, among other things, the Company had finalized the development of a safe and effective syringe, the syringe was slated for imminent mass manufacturing and commercial distribution, and the Company had entered into, or was on the cusp of entering into, binding mass sales and distribution agreements, including a sales agreement with the U.S. Department of Defense. However, contrary to the statements made in the Company’s press releases, the Company had not developed a safe and effective syringe ready for mass manufacturing or commercial distribution, and had not entered into any binding agreements for the sale and distribution of such a final product. The SEC’s complaint further alleges that, through the press releases, the Company artificially inflated the price of the Company’s shares, and that the Company sold shares to a third-party hedge fund at inflated prices. Among other relief, the SEC seeks an order requiring the Company to disgorge approximately $1,000,000 received from its equity line financing from August 2010 through May 2011 with Auctus Private Equity Fund, in addition to other civil penalty amounts, and the SEC is seeking an officer and director bar against its Chief Executive Officer.

	The Company filed its answer on November 8, 2012 and its amended answer on January 21. The discovery is currently ongoing and no trial date has been set by the court. Because discovery is currently ongoing, the Company is not able to project the possible outcome.

	TCA Global Credit Master Fund, L.P.

	On April 26, 2013 (the “Effective Date”), the Company finalized a securities purchase agreement with TCA. Pursuant to the terms of the purchase agreement, TCA shall purchase from the Company up to $2 million of senior secured convertible redeemable debentures. The debentures shall be purchased in a series of closings and pursuant to the first such closing, as of the Effective Date, TCA purchased that certain senior convertible redeemable debenture in the amount of $250,000. The Company’s obligations to TCA under the debentures are secured by that certain security agreement granting TCA an unconditional and continuing first priority security interest in all of the Company’s assets and that certain stock pledge agreement granting TCA a continuing and first priority security interest in certain stock of the Company.

	Under the purchase agreement, as consideration for advisory services provided by TCA to the Company prior to the Effective Date, the Company shall pay to TCA a fee by issuing to TCA that number of shares of the Company’s common stock that equal a dollar amount of $100,000 (the “Advisory Fee Shares”). It is the intention of the Company and TCA that the value of the Advisory Fee Shares shall equal $100,000. In the event the value of the Advisory Fee Shares issued to TCA does not equal $100,000 after the sale of all Advisory Fee Shares, the purchase agreement provides for an adjustment provision allowing for necessary action to adjust the number of shares issued. Additionally, TCA shall receive certain other fees pursuant to the purchase agreement.

Note_11_Preferred_Stock_and_Co

Note 11 - Preferred Stock and Common Stock Transactions	12 Months Ended
Note 11 - Preferred Stock and Common Stock Transactions	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 11 – Preferred Stock and Common Stock Transactions

	Preferred Stock

	Shares Outstanding: Currently, 1,000,000 shares of preferred stock (“Preferred Stock”) are outstanding. Rondald L. Wheet, the Company’s Chairman and Chief Executive Officer, owns 1,000,000 shares of Series 2006 Preferred Stock. Tom O’Brien, the Company’s former President, returned 500,000 shares of Series 2009 Preferred Stock upon his resignation in 2011.

	Dividends: The holder of the Preferred Stock is entitled to receive, ratably, dividends when, as and if declared by the board of directors out of funds legally available therefore. If any dividend or other distributions are declared on our common stock, then a dividend or other distribution must also be declared on the outstanding Preferred Stock at the same time and on the same terms and conditions, so that each holder of Preferred Stock will receive the same dividend or distribution such holder would have received if the holder had converted his Preferred Stock as of the record date for determining stockholders entitled to receive such dividend or distribution.

	Liquidation Preference: In the event of the liquidation, dissolution or winding up, the holders of Preferred Stock are entitled to receive a liquidation preference of $0.001 for each share of Preferred Stock prior to payment being made to any junior stock.

	Conversion: The holders of Preferred Stock may convert each share into 1 share of common stock.

	Preemption: The holders of Preferred Stock have no preemptive rights and they are not subject to further calls or assessments.

	Voting Rights: The holders of Preferred Stock are entitled to 125 votes for each share of common stock into which their Preferred Stock is then convertible (currently 1 share), voting together with our common stock as a single class. Cumulative voting is not permitted. Upon conversion of a share of Preferred Stock, each share of common stock issued upon the conversion will be entitled to only one (1) vote per share.

	Redemption: There are no redemption or sinking fund provisions applicable to the Preferred Stock.

	2013 Common Stock Transactions

	During 2013, the Company issued 8,792,748 shares of common stock with a total value of $609,977 for consulting services, director fees, financing related fees and for wages and consulting fees accrued in 2012. Within the 8,792,748 shares issued, the Company issued 1,378,004 shares for unpaid salaries to the officers of $104,980. The officers will return all remaining shares to the Company if total net proceeds reach the amount of the unpaid salaries. The Company will pay cash or issue additional shares if all shares are sold and net proceeds from the sales do not total the unpaid salaries. At December 31, 2013, the officers have 63,586 shares unsold for unpaid salaries of $28,713. Accordingly, the Company accrued an additional expense of $27,441 which represents the difference between the $28,713 unpaid salaries and the fair market value of the 63,568 shares at December 31, 2013 of $0.02 per share.

	Also, during 2013, the Company received $127,000 cash for the exercise of warrants and options for 2,500,000 shares of common stock and issued 100,000 shares to an investor for proceeds of $12,500 received in 2012.

	Also, during 2013, the Company issued 13,753,045 shares of common stock for the conversions of convertible notes and accrued interest totaling $366,999.

	In addition, during 2013, the Company issued 9,375,000 pledged shares in escrow to TCA as collateral for the securities purchase agreement entered on April 26, 2013.

	Further, the Company cancelled 266,666 shares of common stock on August 27, 2013 previously issued to Globe.

	2012 Common Stock Transactions

	During 2012, 400,000 shares were issued under the terms of the SEC settlement agreement with Gifford Mabie. The initial value of these shares totaled $140,560.

	Also during 2012, the Company issued 2,751,229 shares of common stock with a total value of $516,111 for outside services.

	In addition, the Company issued 1,235,000 shares of common stock for the exercise of warrants and options. The Company received cash of $258,275 and recorded a subscription receivable of $46,000.

	Additionally, the Company issued 13,669,072 shares of common stock for the conversion of convertible notes and accrued interest totaling $1,420,446. The derivative fair value of $898,326 for the conversion feature of these notes was reclassified on the date of conversion to additional paid-in-capital.

Note_12_Stock_Options_and_Warr

Note 12 - Stock Options and Warrants Outstanding	12 Months Ended
Note 12 - Stock Options and Warrants Outstanding	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 12 – Stock Options and Warrants Outstanding

	The Company’s 2007 Stock Option Plan, revised July 2011, permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20 million shares of its common stock. The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company. The plan allows the Company to issue either stock options or common shares.

	From time to time, the Company enters into consulting agreements to perform marketing services for the Company as it begins to enter into the production stage for the RevVac™ Safety Syringe. Consultants are obligated under the contract to promote the product within various spheres of influence. These spheres of influence include, but are not limited to, medical product distributors, hospitals, doctors and government agencies.

	Consultants are issued options at a discount to the market price at the date of issuance. The amount to be determined for the consulting expense is determined based upon the options issued using the Black-Scholes Model.

	During 2013, under the terms of the Company’s 2007 Stock Option Plan, 3,425,000 options were issued for consulting services exercisable at $0.02~$0.50 per share. The options have a term of 10 days to one year and vest upon issuance. The aggregate fair value of these options equal to $86,066 was calculated using the Black-Scholes Model with the following assumptions: (1) discount rate of 0.10% to 0.18% (2) expected life of 0.03 to 1.06 years (3) expected volatility of 163% to 261% and (4) zero expected dividends.

	The following table summarizes the stock option activity:

		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2011		15,473,750		$	0.39		2.45		869,825
	Granted		2,875,000			0.18		0.98
	Exercised		(575,000	)		0.25
	Forfeited or expired		(5,673,750	)
	Outstanding at December 31, 2012		12,100,000			0.2		1.18		150,000
	Granted		3,425,000			0.11		0.56
	Exercised		(2,500,000	)		0.05
	Forfeited or expired		(7,525,000	)
	Outstanding at December 31, 2013		5,500,000			0.12		0.36

	At December 31, 2013, there were 6,249,008 warrants outstanding. 4,166,005 of these warrants are exercisable at $0.125 and 2,083,003 are exercisable at $0.25. The warrants exercisable at $0.125 were originally to expire on March 31, 2013, but were modified to expire on June 30, 2014. The warrants exercisable at $0.25 were originally to expire on March 31 or June 30, 2013, but were modified to expire on September 30, 2014. In addition, the exercise prices of these warrants were reduced on November 20, 2013 from $0.25 to $0.125 in the case of the $0.125 warrants and from $0.50 to $0.25 in the case of the $0.25 warrants. The Company recorded modification expense of $210,373 for the year ended December 31, 2013.

	The following table summarizes the warrant activity:

		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2011		3,371,600			0.39		2.45		-
	Granted		5,739,008			0.33		0.15
	Exercised		(660,000	)		0.5
	Forfeited or expired		(5,570,608	)
	Outstanding at December 31, 2012		2,880,000		$	0.33		0.3		-
	Granted		9,408,015			0.33		1.3
	Exercised		-			-
	Forfeited or expired		(6,039,007	)
	Outstanding at December 31, 2013		6,249,008			0.17		0.34		-

Note_13_Related_Party_Transact

Note 13 - Related Party Transactions	12 Months Ended
Note 13 - Related Party Transactions	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 13 – Related Party Transactions

	On September 1, 2009, the Company entered into a 5-year lease agreement with Osprey South, LLC (“Osprey”), to lease its corporate office space at 670 Marina Drive, Suite 301, Building F, Charleston, South Carolina, 29492. Pursuant to the lease agreement, the Company was to pay Osprey $4,500 per month. On July 1, 2011, the Company amended the lease agreement to include the office space adjacent to the existing office space. Under the amended lease agreement, the lease term ends on June 30, 2016, and the Company is to pay Osprey $10,000 per month. Rondald L. Wheet, the Company’s Chairman and Chief Executive Officer, is the sole member of Osprey. For each of 2013 and 2012, the Company expensed $146,377 (including late fee of $26,377 for the year ended December 31, 2013) in lease payments to Osprey. Rent payable to Osprey was $112,962 and $19,761 as of December 31, 2013 and 2012, respectively. Future minimum lease payments due under the amended lease totaled approximately $300,000 at December 31, 2013.

	During the year ended December 31, 2013, the Company also reimbursed its CEO $31,879 of the self-employment taxes for the years from 2008 to 2010.

	The following table sets forth amounts owed by the Company to its executive officers listed therein for expenses paid by said officers on behalf of the Company as of December 31, 2013 and 2012.

		December 31,
		2013		2012
	Rondald L. Wheet, Chief Executive Officer	$	-	$	32,502
	Stephen Wheet, Director of Sales		9,890		-
	Vincent Olmo, Chief Operating Officer		942		9,194
		$	10,832	$	41,696

	The Company also had a convertible note payable to Mr. Olmo with principal amount of $75,000 and accrued interest of $8,613 at December 31, 2013 and $12,500 advance from shareholder at December 31, 2012.

Note_14_Subsequent_Events

Note 14 - Subsequent Events	12 Months Ended
Note 14 - Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 14 – Subsequent Events

	On February 24, 2014, TCA filed in Florida court to seek unpaid monthly payments plus late fees and penalties on the note issued on May 1, 2013 as part of the credit facility agreement. The Company was delinquent on payments and was notified of default on January 22, 2014. .

	Subsequent to December 31, 2013, the Company issued 500,000 common shares valued at $17,500 to repay outstanding payable for the same amount; issued 1,000,000 common shares for proceeds of $20,000; issued 1,000,000 shares, valued at $27,500 based on the market price on the issuance date, for consulting services; and issued 2,440,149 shares for conversion of notes payable and accrued interest in the amount of $36,400.

	Subsequent to December 31, 2013, the Company also issued 788,250 shares to settle unpaid salary of the officers.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Accounting Policies, by Policy (Policies) [Line Items]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers highly liquid investments (those readily convertible to cash) purchased with original maturity dates of three months or less to be cash equivalents.

Trade and Other Accounts Receivable, Policy [Policy Text Block]

Accounts Receivable

Inventory, Policy [Policy Text Block]

Inventory

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Depreciation and amortization expense is recorded on a straight-line basis over the estimated useful life of the asset as listed below:

Asset Category

Useful Lives

Machinery and equipment (years)

Furniture and fixtures (years)

Leasehold improvements

Shorter of leasehold improvement life or remaining term of lease

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangibles

Intangible assets include patents and trademarks, which are valued at cost and amortized on a straight-line basis over periods varying from 17 to 20 years.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-lived Assets

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are expensed as incurred. The Company incurred $0 and $35,544 of research and development expenses for the years ended December 31, 2013 and 2012.

Derivatives, Policy [Policy Text Block]

Derivative Instruments

Fair Value Measurement, Policy [Policy Text Block]

Fair Value of Financial Instruments

●

Level 1 – quoted prices in active markets for identical assets or liabilities.

●

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

●

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at December 31, 2013, for assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Payable for indemnification

—

1,376,084

—

1,376,084

Derivative liability

—

658,453

The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Payable for indemnification

—

1,347,806

—

1,347,806

Derivative liability

—

364,802

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-based Compensation

Income Tax, Policy [Policy Text Block]

Income Taxes

Earnings Per Share, Policy [Policy Text Block]

Earnings (Loss) Per Common Share

Subsequent Events, Policy [Policy Text Block]

Subsequent Events

Use of Estimates, Policy [Policy Text Block]

Critical Accounting Estimates

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain prior period amounts have been reclassified to conform to current period presentation.

New Accounting Pronouncements, Policy [Policy Text Block]

New and Pending Accounting Standards

Beneficial Conversion Feature [Member]

Accounting Policies, by Policy (Policies) [Line Items]

Derivatives, Policy [Policy Text Block]

Beneficial Conversion Feature

Note_1_Basis_of_Presentation_D1

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Tables)	12 Months Ended
	Dec. 31, 2013
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Tables) [Line Items]	'
Property, Plant and Equipment [Table Text Block]	'
		December 31,
		2013			2012

	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(176,193	)		(89,726	)
		$	270,189		$	356,656
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
		Level 1			Level 2			Level 3		Total
	Payable for indemnification	$	—		$	1,376,084		$	—	$	1,376,084

	Derivative liability	$	—		$	—		$	658,453	$	658,453
		Level 1			Level 2			Level 3		Total
	Payable for indemnification	$	—		$	1,347,806		$	—	$	1,347,806

	Derivative liability	$	—		$	—		$	364,802	$	364,802
Estimated Useful Life [Member]	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Tables) [Line Items]	'
Property, Plant and Equipment [Table Text Block]	'
	Asset Category	Useful Lives
	Machinery and equipment (years)	5
	Furniture and fixtures (years)	7
	Leasehold improvements	Shorter of leasehold improvement life or remaining term of lease

Note_3_Property_And_Equipment_

Note 3 - Property And Equipment (Tables)	12 Months Ended
Note 3 - Property And Equipment (Tables)	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		December 31,
		2013			2012

	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(176,193	)		(89,726	)
		$	270,189		$	356,656

Note_4_Intangibles_Tables

Note 4 - Intangibles (Tables)	12 Months Ended
Note 4 - Intangibles (Tables)	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		December 31,
		2013			2012
	Patent	$	184,906		$	146,538
	Less accumulated amortization		(51,389	)		(39,851	)
		$	133,517		$	106,687

Note_5_Accounts_Payable_and_Ac1

Note 5 - Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
Note 5 - Accounts Payable and Accrued Liabilities (Tables)	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		December 31,
		2013		2012
	Accounts payable	$	565,127	$	432,436
	Accrued payroll liabilities and related penalties		607,134		411,670
	Accrued salary		418,440		143,167
	Accrued interest		158,869		134,559
	Other accruals		117,622		539
		$	1,867,192	$	1,122,371

Note_8_Convertible_Notes_Table

Note 8 - Convertible Notes (Tables)	12 Months Ended
Note 8 - Convertible Notes (Tables)	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Short-term Debt [Table Text Block]	'
		December 31,
		2013			2012
	Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014	$	191,663		$	191,663
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on March 21, 2013, fully converted in 2013		-			7,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 10, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on August 27, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 19, 2014		35,000			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on July 23, 2014		42,500			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on September 12, 2014		47,500			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on June 30, 2014		32,500			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on July 29, 2014		10,000			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on August 29, 2014		17,500			-
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due on January 3, 2013		-			62,165
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due monthly until April 26, 2014		189,844			-
	Convertible Promissory Notes Payable issued in the course of a private placement to individual, unsecured, interest rate of 12% per annum, with payment due on April 9, 2014 or subsequently on demand by holder		140,862
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on September 3, 2014		35,000			-
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on January 26, 2014		75,000			100,000
			817,369			446,328
	Less: debt discount		(247,661	)		(229,573	)
		$	569,708		$	216,755

Note_9_Derivatives_Note_Conver1

Note 9 - Derivatives - Note Conversion Feature (Tables)	12 Months Ended
Note 9 - Derivatives - Note Conversion Feature (Tables)	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Derivative Instruments [Table Text Block]	'
	Fair value at December 31, 2011	$	442,311
	Decrease in value		(131,397	)
	Addition		952,214
	Reclassification from liability to equity as a result of note conversions and repayment		(898,326	)
	Fair value at December 31, 2012		364,802
	Decrease in value		(304,994	)
	Addition		674,167
	Reclassification from liability to equity as a result of note conversions and repayment		(75,522	)
	Fair value at December 31, 2013	$	658,453
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	'
		December 31,
		2013					2012
	Risk free interest rate			0.13		%		0.11%	to	0.16	%
	Expected life (years)		0.07	to	0.7			0.01	to	2.1
	Dividend Yield			0		%			0		%
	Volatility		256%	to	394	%		130%	to	219	%
		Variant issuance date during years ended December 31,
		2013					2012
	Risk free interest rate		0.10	to	0.15	%		0.1	to	0.12	%
	Expected life (years)		0.5	to	0.99			0.23	to	2.1
	Dividend Yield			0		%			0		%
	Volatility		213%	to	293	%		130%	to	156	%

Note_12_Stock_Options_and_Warr1

Note 12 - Stock Options and Warrants Outstanding (Tables)	12 Months Ended
Note 12 - Stock Options and Warrants Outstanding (Tables)	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2011		15,473,750		$	0.39		2.45		869,825
	Granted		2,875,000			0.18		0.98
	Exercised		(575,000	)		0.25
	Forfeited or expired		(5,673,750	)
	Outstanding at December 31, 2012		12,100,000			0.2		1.18		150,000
	Granted		3,425,000			0.11		0.56
	Exercised		(2,500,000	)		0.05
	Forfeited or expired		(7,525,000	)
	Outstanding at December 31, 2013		5,500,000			0.12		0.36
		Number of			Weighted-		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
		Shares			average
		Under Option			Exercise
					Price
	Outstanding at December 31, 2011		3,371,600			0.39		2.45		-
	Granted		5,739,008			0.33		0.15
	Exercised		(660,000	)		0.5
	Forfeited or expired		(5,570,608	)
	Outstanding at December 31, 2012		2,880,000		$	0.33		0.3		-
	Granted		9,408,015			0.33		1.3
	Exercised		-			-
	Forfeited or expired		(6,039,007	)
	Outstanding at December 31, 2013		6,249,008			0.17		0.34		-

Note_13_Related_Party_Transact1

Note 13 - Related Party Transactions (Tables)	12 Months Ended
Note 13 - Related Party Transactions (Tables)	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
		December 31,
		2013		2012
	Rondald L. Wheet, Chief Executive Officer	$	-	$	32,502
	Stephen Wheet, Director of Sales		9,890		-
	Vincent Olmo, Chief Operating Officer		942		9,194
		$	10,832	$	41,696

Note_1_Basis_of_Presentation_D2

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) (USD $)	12 Months Ended		208 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) [Line Items]	'	'	'
Research and Development Expense (in Dollars)	$0	$35,544	$2,935,949
Stock Options and Warrants [Member]	'	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,749,008	14,980,000	'
Convertible Debt Securities [Member]	'	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) [Line Items]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	52,530,562	6,603,582	'
Minimum [Member]	'	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'17 years	'	'
Maximum [Member]	'	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'	'

Note_1_Basis_of_Presentation_D3

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) - Estimated Useful Lives of Property Plant and Equipment	12 Months Ended
	Dec. 31, 2012
Machinery and Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Estimated Useful Lives	'5 years
Furniture and Fixtures [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and Equipment, Estimated Useful Lives	'7 years
Leasehold Improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Leasehold improvements	'Shorter of leasehold improvement life or remaining term of lease

Note_1_Basis_of_Presentation_D4

Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis (USD $)	Dec. 31, 2013	Dec. 31, 2012
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Cash and cash equivalents	$1,376,084	$1,347,806
Derivative liability	658,453	364,802
Fair Value, Inputs, Level 2 [Member]	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Cash and cash equivalents	1,376,084	1,347,806
Fair Value, Inputs, Level 3 [Member]	'	'
Note 1 - Basis of Presentation, Description of Business, Significant Accounting Policies, Critical Accounting Estimates and Reclassifications (Details) - Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]	'	'
Derivative liability	$658,453	$364,802

Note_2_Going_Concern_Details

Note 2 - Going Concern (Details) (USD $)

1 Months Ended

12 Months Ended

16 Months Ended

208 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Dec. 31, 2000

Dec. 31, 1999

Dec. 31, 1998

Dec. 31, 1997

Dec. 31, 2013

Going Concern [Abstract]

Net Income (Loss) Attributable to Parent

($6,424,539)

($7,164,311)

($4,541,518)

($3,231,425)

($2,463,751)

($1,335,154)

($4,475,017)

($598,302)

($1,310,783)

($1,552,008)

($1,391,518)

($1,933,676)

($2,199,085)

($1,347,859)

($1,014,555)

($2,584,383)

($795,376)

($44,363,260)

Working Capital Defecit

$7,642,006

Note_3_Property_And_Equipment_1

Note 3 - Property And Equipment (Details) (USD $)	12 Months Ended		208 Months Ended		1 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jan. 02, 2013	Dec. 31, 2012	Nov. 30, 2012	Dec. 31, 2012	Jan. 02, 2013	Dec. 31, 2011	Dec. 31, 2012
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jan. 02, 2013	Mold Production Payments [Member]	Mold Production Payments [Member]	Mold Production Payments [Member]	Mold Production Payments [Member]	Mold Production Payments [Member]	Medical Investment Group (MIG) [Member]
Note 3 - Property And Equipment (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Depreciation	$86,467	$69,008	'	'	'	'	'	'	'	'
Asset Impairment Charges	'	878,276	4,570,007	'	50,000	710,000	710,000	'	'	'
Property, Plant and Equipment, Gross	446,382	446,382	446,382	'	50,000	'	50,000	10,000	760,000	'
Prepayment Write Off	'	'	'	'	'	'	80,000	'	'	'
Gain Contingency, Unrecorded Amount	'	'	'	$770,000	'	'	'	'	'	$770,000

Note_3_Property_And_Equipment_2

Note 3 - Property And Equipment (Details) - Summary of Property And Equipment (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$446,382	$446,382
Less accumulated depreciation	-176,193	-89,726
	270,189	356,656
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	353,235	353,235
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	44,000	44,000
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$49,147	$49,147

Note_4_Intangibles_Details

Note 4 - Intangibles (Details) (USD $)	12 Months Ended
Note 4 - Intangibles (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Note 4 - Intangibles (Details) [Line Items]	'	'
Amortization of Intangible Assets	$11,538	$33,963
Licensing Agreements [Member]	'	'
Note 4 - Intangibles (Details) [Line Items]	'	'
Impairment of Intangible Assets, Finite-lived	'	$15,000

Note_4_Intangibles_Details_Sum

Note 4 - Intangibles (Details) - Summary of Intangible Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Less accumulated amortization	($51,389)	($39,851)
	133,517	106,687
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Patent	$184,906	$146,538

Note_5_Accounts_Payable_and_Ac2

Note 5 - Accounts Payable and Accrued Liabilities (Details) (USD $)

12 Months Ended

208 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Related to Minimum Purchase Requirement [Member]

Product Purchase [Member]

Equipment Purchase [Member]

Yeso Med [Member]

Note 5 - Accounts Payable and Accrued Liabilities (Details) [Line Items]

Accrued Payroll Taxes, Current

$607,134

$411,670

$607,134

Tax Lien, Amount

6,164

Long-term Purchase Commitment, Time Period

'5-year

Long-term Purchase Commitment, Minimum Quantity Required

2,500,000

Purchase Commitment, Percentage of Supply Price

50.00%

Accounts Payable, Current

2,749,075,000,000

783,593

208,501

208,258

289,519

289,009

3,247,095

1,280,860

Loss on Purchase Commitments

$1,965,482

$783,593

$2,749,075

$1,965,482,000,000

$783,593

Note_5_Accounts_Payable_and_Ac3

Note 5 - Accounts Payable and Accrued Liabilities (Details) - Summary of Accounts Payable and Accrued Liabilities (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of Accounts Payable and Accrued Liabilities [Abstract]	'	'
Accounts payable	$565,127	$432,436
Accrued payroll liabilities and related penalties	607,134	411,670
Accrued salary	418,440	143,167
Accrued interest	158,869	134,559
Other accruals	117,622	539
	$1,867,192	$1,122,371

Note_7_Payable_for_Indemnifica1

Note 7 - Payable for Indemnification (Details) (USD $)	0 Months Ended		12 Months Ended
Note 7 - Payable for Indemnification (Details) (USD $)	Mar. 15, 2012	Dec. 14, 2010	Dec. 31, 2013	Dec. 31, 2012	Mar. 11, 2005
Disclosure Text Block [Abstract]	'	'	'	'	'
	'	'	$1,376,084	$1,347,806	$1,088,067
Stock Issued During Period, Shares, for Indemnification (in Shares)	400,000	400,000	'	'	'
Stock Issued During Period, Value, for Indemnification	140,560	184,000	'	'	'
Net Loss on Stock Held in Special Account for Indemnification	'	'	$28,278	$63,347	'
Common Stock Held In Special Account For Indemnification Shares (in Shares)	'	'	301,463	'	'

Note_8_Convertible_Notes_Detai

Note 8 - Convertible Notes (Details) (USD $)

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

16 Months Ended

208 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

8 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

2 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

2 Months Ended

12 Months Ended

0 Months Ended

8 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Nov. 03, 2005

Nov. 20, 2013

Jun. 11, 2013

9-May-13

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2004

Dec. 31, 2003

Dec. 31, 2002

Dec. 31, 2001

Dec. 31, 1998

Dec. 31, 1997

Dec. 31, 2013

Jan. 03, 2012

Apr. 26, 2013

Dec. 31, 2013

Dec. 31, 2012

Oct. 09, 2013

Dec. 31, 2013

Apr. 25, 2013

Nov. 20, 2013

Dec. 31, 2012

Dec. 31, 2013

Apr. 25, 2013

Nov. 20, 2013

Dec. 31, 2012

Apr. 25, 2013

Mar. 02, 2013

Aug. 28, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jan. 03, 2012

Dec. 31, 2012

Feb. 22, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 10, 2013

Oct. 21, 2013

Feb. 28, 2013

Dec. 31, 2013

Aug. 15, 2013

Dec. 10, 2013

Aug. 15, 2013

Dec. 31, 2013

Oct. 21, 2013

Feb. 28, 2013

Dec. 24, 2013

Nov. 27, 2013

Oct. 31, 2013

Mar. 19, 2013

Dec. 24, 2013

Dec. 31, 2013

9-May-13

Jan. 03, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 03, 2012

Apr. 26, 2013

Dec. 31, 2013

9-May-13

Dec. 31, 2013

Apr. 26, 2013

Dec. 31, 2013

Dec. 31, 2012

Oct. 09, 2013

Sep. 03, 2013

Apr. 25, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Stock Issued as Collateral [Member]

Related to Conversion Feature [Member]

Convertible Debt [Member]

Warrant 0.25 [Member]

Warrant .50 [Member]

Warrants, Related to Individual Convertible Notes [Member]

October 21 and December 19 Notes [Member]

October 31, November 27 and December 24 Notes [Member]

September 3, 2013 Note [Member]

Chief Operating Officer [Member]

TCA Global Credit Master Fund, LP [Member]

JMJ Note [Member]

Asher Notes 2012 [Member]

Asher Note 2013 [Member]

Carebourn Note 2013 [Member]

TCA Note [Member]

2013 TCA Purchase Agreement [Member]

TCA Debentures [Member]

Individual Convertible Notes [Member]

Individual Convertible Notes 2013 [Member]

Minimum [Member]

Maximum [Member]

TCA Debentures [Member]

Individual Convertible Notes [Member]

Individual Convertible Notes 2013 [Member]

Minimum [Member]

Maximum [Member]

Asher Note 2013 [Member]

Carebourn Note 2013 [Member]

Individual Convertible Notes 2013 [Member]

Individual Convertible Notes [Member]

Note 8 - Convertible Notes (Details) [Line Items]

Convertible Notes Payable

$75,000

$1,050,000

$191,663

$225,000

$250,000

$35,000

$50,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

8.00%

12.00%

8.00%

Percentage Of Common Stock Closing Price

70.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.02

$0.00

Debt Conversion, Converted Instrument, Amount

1,420,446

15,498

92,500

42,500

60,000

27,840

25,000

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

13,753,045

13,669,072

180,000

2,726,118

4,857,358

3,779,454

1,750,000

300,000

1,111,825

353,727

1,000,000

Debt Instrument, Unamortized Discount

42,534

94,486

45,264

23,398

42,534

450,000

11,229

106,691

17,500

53,859

55,952

19,424

Interest Expense, Debt

182,733

95,462

80,000

11,781

42,534

885,418

2,837

11,602

Proceeds from Notes Payable

47,500

42,500

35,000

Debt Instrument, Convertible, Beneficial Conversion Feature

170,639

237,774

94,624

266,925

42,500

49,091

115,642

174,448

218,053

777,766

35,709

37,837

Interest on Convertible Debt, Net of Tax

-200,404

-182,733

-596,878

66,930

141,925

30,514

55,642

14,736

16,285

Proceeds from Convertible Debt

17,500

10,000

32,500

60,000

140,862

Amortization of Debt Discount (Premium)

571,639

1,428,978

2,432,857

49,091

Common Stock Purchase Agreement, Amount to be Purchased

2,000,000

Facility Fee Payable

100,000

Stock Issued During Period, Shares, New Issues (in Shares)

250,000

100,000

9,375,000

559,268

Facility Fee Satisfied

51,924

100,000

Debt Instrument, Multiplier to Calculate Conversion Price

95.00%

Stock Issued During Period, Value, Conversion of Convertible Securities

366,999

2,318,772

962,296

530,756

306,741

133,030

18,750

69,201

102,803

7,500

55,000

129,000

140,000

Debt Conversion, Original Debt, Amount

106,987

Gains (Losses) on Extinguishment of Debt

-34,202

13,202

-173,914

-33,013

Leak Out Provision Threshold Amount

80,000

100,000

Sale of Stock Third Party, Number of Shares Issued in Transaction (in Shares)

638,175

Sale of Stock Third Party Consideration Received on Transaction

28,122

Increase (Decrease) in Other Accrued Liabilities

29,642

60,000

Share Price (in Dollars per share)

$0.02

Fair Value Inputs, Discount Rate

7.00%

Repayments of Notes Payable

77,656

Debt Instrument Convertible Price Percentage of Weighted Average Price of Common Stock

85.00%

Stock Issued During Period, Value, New Issues

625,066

516,111

9,375

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)

2,000,000

Debt Issuance Cost

160,000

Unsold Shares (in Shares)

2,000,000

Proceeds from Issuance of Debt

762,602

1,450,501

3,738,603

956,501

Percentage of Average Daily Volume

75.00%

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

140,000

200,000

3,826,005

70,000

100,000

1,913,003

2,859,008

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

0.25

0.125

0.25

0.5

0.25

0.5

Proceeds From Issuance of Debt Allocated to Warrants

347,097

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$589,416

Fair Value Assumptions, Risk Free Interest Rate

0.13%

3.90%

0.11%

0.16%

Fair Value Assumptions, Expected Volatility Rate

155.60%

218.64%

256.00%

130.00%

394.00%

219.00%

Fair Value Assumptions, Expected Dividend Payments (in Dollars per share)

Fair Value Assumptions, Expected Term

'109 days

'1 year

'25 days

'3 days

'255 days

'2 years 36 days

Modification Expense

148,127

40,501

Fair Value Adjustment of Warrants

21,745

Warrants and Rights Outstanding

$3,526

$2,588

Threshold for Convertible Notes Beneficial Ownership

4.99%

Note_8_Convertible_Notes_Detai1

Note 8 - Convertible Notes (Details) - Notes Payable (USD $)	Dec. 31, 2013	Dec. 31, 2012
Short-term Debt [Line Items]	'	'
Less: debt discount	$0	($42,534)
	494,708	184,289
Including Related Parties [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	817,369	446,328
Less: debt discount	-247,661	-229,573
	569,708	216,755
Private Placement [Member] \| Due September 3, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	35,000	'
Private Placement [Member] \| Due on January 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	75,000	100,000
JMJ Financial Inc [Member] \| Due February 22, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	191,663	191,663
Asher Enterprises Inc [Member] \| Due March 21, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	7,500
Asher Enterprises Inc [Member] \| Due May 10, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	42,500
Asher Enterprises Inc [Member] \| Due August 27, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	42,500
Asher Enterprises Inc [Member] \| Due May 19, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	35,000	'
Asher Enterprises Inc [Member] \| Due September 19, 2012 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	42,500	'
Asher Enterprises Inc [Member] \| Due September 12, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	47,500	'
Carebourn Capital L.P. [Member] \| Due December 19, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	32,500	'
Carebourn Capital L.P. [Member] \| Due July 29, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	10,000	'
Carebourn Capital L.P. [Member] \| Due August 29, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	17,500	'
TCA Global Credit Master Fund, LP [Member] \| Due January 3, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	62,165
TCA Global Credit Master Fund, LP [Member] \| Due April 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	189,844	'
Individual Counterparty [Member] \| Due April 9, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	$140,862	'

Note_8_Convertible_Notes_Detai2

Note 8 - Convertible Notes (Details) - Notes Payable (Parentheticals)	Dec. 31, 2013	Dec. 31, 2012
Private Placement [Member] \| Due September 3, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Private Placement [Member] \| Due on January 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
JMJ Financial Inc [Member] \| Due February 22, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Asher Enterprises Inc [Member] \| Due March 21, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Asher Enterprises Inc [Member] \| Due May 10, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Asher Enterprises Inc [Member] \| Due August 27, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Asher Enterprises Inc [Member] \| Due May 19, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Asher Enterprises Inc [Member] \| Due September 19, 2012 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Asher Enterprises Inc [Member] \| Due September 12, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Carebourn Capital L.P. [Member] \| Due December 19, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Carebourn Capital L.P. [Member] \| Due July 29, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
Carebourn Capital L.P. [Member] \| Due August 29, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	8.00%	8.00%
TCA Global Credit Master Fund, LP [Member] \| Due January 3, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	12.00%	12.00%
TCA Global Credit Master Fund, LP [Member] \| Due April 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	12.00%	12.00%
Individual Counterparty [Member] \| Due April 9, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convеrtiblе Promissory Notе Payablе, Intеrеst ratе	12.00%	12.00%

Note_9_Derivatives_Note_Conver2

Note 9 - Derivatives - Note Conversion Feature (Details) - Reconciliation of Derivative Liability (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2011	Dec. 30, 2011
Reconciliation of Derivative Liability [Abstract]	'	'	'
Fair Value at	$364,802	'	$442,311
Decrease in value	-304,994	-131,397	'
Addition	674,167	952,214	'
Reclassification from liability to equity as a result of note conversions and repayment	-75,522	-898,326	'
Fair Value at	$658,453	'	$442,311

Note_9_Derivatives_Note_Conver3

Note 9 - Derivatives - Note Conversion Feature (Details) - Fair Value Assumptions, Derivative Liability	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	0.13%	'
Dividend Yield	0.00%	0.00%
Variant Issuance Date [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Dividend Yield	0.00%	0.00%
Variant Issuance Date [Member] \| Minimum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	0.10%	0.10%
Expected life	'6 months	'83 days
Volatility	213.00%	130.00%
Variant Issuance Date [Member] \| Maximum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	0.15%	0.12%
Expected life	'361 days	'2 years 36 days
Volatility	293.00%	156.00%
Minimum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	'	0.11%
Expected life	'25 days	'3 days
Volatility	256.00%	130.00%
Maximum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	'	0.16%
Expected life	'255 days	'2 years 36 days
Volatility	394.00%	219.00%

Note_10_Commitments_and_Contin1

Note 10 - Commitments and Contingencies (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

208 Months Ended

12 Months Ended

1 Months Ended

11 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

Jun. 11, 2013

6-May-13

Jan. 02, 2013

Nov. 03, 2005

Sep. 20, 2012

Oct. 21, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Aug. 27, 2013

Dec. 31, 2013

Apr. 26, 2013

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2012

Jan. 02, 2013

Dec. 31, 2011

Jan. 30, 2012

Jan. 09, 2012

Sep. 30, 2005

Mar. 15, 2012

Apr. 26, 2013

6-May-13

Restricted Stock [Member]

Advisory Fee Requirement [Member]

Mold Production Payments [Member]

JMJ Financial Inc [Member]

Maxxon Inc [Member]

Globe Med Tech Inc. [Member]

JMJ Financial Inc [Member]

TCA Debentures [Member]

Cash Disbursement [Member]

Annuity Payments [Member]

Former President and Director [Member]

Note 10 - Commitments and Contingencies (Details) [Line Items]

Purchase Obligation

$1,500,000

Purchase Price of Stock Percent

22.50%

Payments for Fees

10,000

Stock Issued During Period, Shares, New Issues (in Shares)

250,000

100,000

Intangible Asset, Patent, Ownership Percentage

50.00%

Joint Venture, Ownership Percentage

50.00%

Stock Issued During Period, Value, New Issues

625,066

516,111

Litigation Settlement, Amount

311,440

125,000

320,000

Litigation Settlement Shares (in Shares)

266,666

Shares Cancelled (in Shares)

266,666

Gain Contingency, Unrecorded Amount

770,000

Proceeds from Legal Settlements

1,000,000

Property, Plant and Equipment, Gross

446,382

50,000

10,000

760,000

Asset Impairment Charges

878,276

4,570,007

50,000

710,000

Litigation Settlement Annuity Term

'4 years

Loss Contingency Damages Sought Shares (in Shares)

3,000,000

Requested Shares Of Common Stock Conversion (in Shares)

1,226,049

1,000,000

2,226,049

Loss Contingency, Damages Sought, Value

1,000,000

Securities Purchase Agreement Amount To Be Purchased

2,000,000

Convertible Notes Payable

250,000

Other Commitment

$100,000

Note_11_Preferred_Stock_and_Co1

Note 11 - Preferred Stock and Common Stock Transactions (Details) (USD $)	0 Months Ended		1 Months Ended	12 Months Ended						208 Months Ended
	Jun. 11, 2013	Nov. 03, 2005	Aug. 27, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2006	Dec. 31, 2004	Dec. 31, 2000	Dec. 31, 2013
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Preferred Stock, Shares Outstanding	'	'	'	1,000,000	1,000,000	'	'	'	'	1,000,000
Preferred Stock, Voting Rights	'	'	'	'125	'	'	'	'	'	'
Common Stock, Voting Rights	'	'	'	'one	'	'	'	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	'	'	'	2,751,229	'	'	'	'	'
Stock Issued During Period, Value, Issued for Services (in Dollars)	'	'	'	$609,977	'	'	'	'	$405,000	'
Accrued Salaries (in Dollars)	'	'	'	418,440	143,167	'	'	'	'	418,440
Increase (Decrease) in Accrued Liabilities (in Dollars)	'	'	'	27,441	'	'	'	'	'	'
Share Price (in Dollars per share)	'	'	'	$0.02	'	'	'	'	'	$0.02
Proceeds from Warrant Exercises (in Dollars)	'	'	'	'	'	'	6,000	72,100	'	'
Stock Issued During Period, Shares, New Issues	250,000	'	'	100,000	'	'	'	'	'	'
Proceeds from Issuance of Common Stock (in Dollars)	'	'	'	'	12,500	'	'	'	'	8,163,410
Debt Conversion, Converted Instrument, Shares Issued	'	'	'	13,753,045	13,669,072	'	'	'	'	'
Treasury Stock, Shares, Retired	'	'	266,666	'	'	'	'	'	'	'
Stock Issued During Period, Value, New Issues (in Dollars)	'	625,066	'	'	516,111	'	'	'	'	'
Stockholders' Equity Note, Subscriptions Receivable (in Dollars)	'	'	'	71,000	71,000	'	'	'	'	71,000
Debt Conversion, Converted Instrument, Amount (in Dollars)	'	'	'	'	1,420,446	'	'	'	'	'
Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)	'	'	'	170,639	237,774	94,624	'	'	'	'
Warrants and Options Exercised [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Proceeds from Warrant Exercises (in Dollars)	'	'	'	127,000	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	2,500,000	1,235,000	'	'	'	'	'
Stock Issued During Period, Value, New Issues (in Dollars)	'	'	'	'	258,275	'	'	'	'	'
Stockholders' Equity Note, Subscriptions Receivable (in Dollars)	'	'	'	'	46,000	'	'	'	'	'
Converted into Shares [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Interest Expense, Debt (in Dollars)	'	'	'	366,999	'	'	'	'	'	'
Stock Issued as Collateral [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	9,375,000	'	'	'	'	'	'
Series 2009 Preferred Stock [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock Repurchased and Retired During Period, Shares	'	'	'	'	500,000	'	'	'	'	'
Series 2006 Preferred Stock [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)	'	'	'	$0.00	'	'	'	'	'	$0.00
Stock Issued During Period, Shares, Issued for Services	'	'	'	8,792,748	'	'	'	'	'	'
Chief Executive Officer [Member] \| Series 2006 Preferred Stock [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Preferred Stock, Shares Outstanding	'	'	'	'	1,000,000	'	'	'	'	'
Officer [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	'	'	1,378,004	'	'	'	'	'	'
Stock Issued During Period, Value, Issued for Services (in Dollars)	'	'	'	104,980	'	'	'	'	'	'
Unsold Shares	'	'	'	63,586	'	'	'	'	'	63,586
Accrued Salaries (in Dollars)	'	'	'	28,713	'	'	'	'	'	28,713
Gifford Mabie [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	'	400,000	'	'	'	'	'
Stock Issued During Period, Value, New Issues (in Dollars)	'	'	'	'	$140,560	'	'	'	'	'
Series 2006 Preferred Stock [Member]	'	'	'	'	'	'	'	'	'	'
Note 11 - Preferred Stock and Common Stock Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Preferred Stock, Shares Outstanding	'	'	'	'	1,000,000	'	'	'	'	'

Note_12_Stock_Options_and_Warr2

Note 12 - Stock Options and Warrants Outstanding (Details) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jul. 31, 2011

Dec. 31, 2013

Nov. 20, 2013

Dec. 31, 2013

Nov. 20, 2013

Dec. 31, 2013

For Consulting Services Exercisable $0.05 - $0.50 [Member]

For Consulting Services Exercisable at $0.05 [Member]

For Consulting Services Exercisable at $0.50 [Member]

Exercise Price A [Member]

Exercise Price B [Member]

Employee Stock Option [Member]

Minimum [Member]

Maximum [Member]

Reduced From [Member]

Reduced To [Member]

Reduced From [Member]

Reduced To [Member]

Minimum [Member]

Maximum [Member]

Note 12 - Stock Options and Warrants Outstanding (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

20,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

3,425,000

2,875,000

3,425,000

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)

$0.02

$0.50

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

'131 days

'1 year 65 days

'2 years 164 days

'10 days

'1 year

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)

$86,066

Fair Value Inputs, Discount Rate

0.10%

0.18%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

'10 days

'1 year 21 days

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum

163.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

261.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in Shares)

6,249,008

Share-Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number (in Shares)

4,166,005

2,083,003

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.125

0.25

0.125

0.25

0.5

0.25

Note_12_Stock_Options_and_Warr3

Note 12 - Stock Options and Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 12 - Stock Options and Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities [Line Items]	'	'	'
Number of Shares Under Option	5,500,000	12,100,000	15,473,750
Weighted-average Exercise Price (in Dollars per share)	$0.12	$0.20	$0.39
Weighted Average Remaining Contractual Term (in years)	'131 days	'1 year 65 days	'2 years 164 days
Aggregate Intrinsic Value (in Dollars)	'	$150,000	$869,825
Number of Shares Under Option	6,249,008	'	'
Number of Shares Under Option	3,425,000	2,875,000	'
Weighted-average Exercise Price (in Dollars per share)	$0.11	$0.18	'
Weighted Average Remaining Contractual Term (in years)	'204 days	'357 days	'
Number of Shares Under Option	-2,500,000	-575,000	'
Weighted-average Exercise Price (in Dollars per share)	$0.05	$0.25	'
Number of Shares Under Option	-7,525,000	-5,673,750	'
Warrant [Member]	'	'	'
Note 12 - Stock Options and Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities [Line Items]	'	'	'
Number of Shares Under Option	6,249,008	2,880,000	3,371,600
Weighted-average Exercise Price (in Dollars per share)	$0.17	$0.33	$0.39
Weighted Average Remaining Contractual Term (in years)	'124 days	'109 days	'2 years 164 days
Number of Shares Under Option	9,408,015	5,739,008	'
Weighted-average Exercise Price (in Dollars per share)	$0.33	$0.33	'
Weighted Average Remaining Contractual Term (in years)	'1 year 109 days	'54 days	'
Number of Shares Under Option	'	-660,000	'
Weighted-average Exercise Price (in Dollars per share)	'	$0.50	'
Number of Shares Under Option	-6,039,007	-5,570,608	'

Note_13_Related_Party_Transact2

Note 13 - Related Party Transactions (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jul. 01, 2011	Sep. 01, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
			Late Fees [Member]	Osprey South, LLC [Member]	Osprey South, LLC [Member]	Osprey South, LLC [Member]	Osprey South, LLC [Member]	Chief Operating Officer [Member]	Shareholder [Member]	Reimbursement of Prior Years' Self-Employment Taxes [Member]
			Osprey South, LLC [Member]	5 Year Lease Agreement [Member]	5 Year Lease Agreement [Member]
Note 13 - Related Party Transactions (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Lease Agreement Monthly Payment	'	'	'	$10,000	$4,500	'	'	'	'	'
Operating Leases, Rent Expense	'	'	26,377	'	'	146,377	'	'	'	'
Accrued Rent	'	'	'	'	'	112,962	19,761	'	'	'
Operating Leases, Future Minimum Payments Due	'	'	'	'	'	300,000	'	'	'	'
Related Party Transaction, Amounts of Transaction	'	'	'	'	'	'	'	'	'	31,879
Convertible Notes Payable	'	'	'	'	'	'	'	75,000	'	'
Interest Payable	158,869	134,559	'	'	'	'	'	8,613	'	'
Related Party Transaction, Due from (to) Related Party	'	'	'	'	'	'	'	'	$12,500	'

Note_13_Related_Party_Transact3

Note 13 - Related Party Transactions (Details) - Amounts Owed by the Company to its Executive Officers (USD $)	Dec. 31, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]	'	'
Related Party	$10,832	$41,696
Chief Executive Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Related Party	'	32,502
Director of Sales [Member]	'	'
Related Party Transaction [Line Items]	'	'
Related Party	9,890	'
Chief Operating Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Related Party	$942	$9,194

Note_14_Subsequent_Events_Deta

Note 14 - Subsequent Events (Details) (USD $)	0 Months Ended		12 Months Ended			4 Months Ended
	Jun. 11, 2013	Nov. 03, 2005	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2000	Apr. 30, 2013	Apr. 30, 2013	Apr. 30, 2013	Apr. 30, 2013
						Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
						For Settlement of Accrued Salaries [Member]	For Settlement of Accounts Payable [Member]	For Director Fees [Member]
Note 14 - Subsequent Events (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	13,753,045	13,669,072	'	'	'	'	500,000
Debt Conversion, Converted Instrument, Amount (in Dollars)	'	'	'	$1,420,446	'	'	'	'	$17,500
Stock Issued During Period, Shares, New Issues	250,000	'	100,000	'	'	1,000,000	1,000,000	788,250	'
Stock Issued During Period, Value, New Issues (in Dollars)	'	625,066	'	516,111	'	20,000	27,500	'	'
Stock Issued During Period, Shares, Issued for Services	'	'	'	2,751,229	'	'	'	'	2,440,149
Stock Issued During Period, Value, Issued for Services (in Dollars)	'	'	$609,977	'	$405,000	'	'	'	$36,400